<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Alzheimers Res Ther</journal-id><journal-id journal-id-type="iso-abbrev">Alzheimers Res Ther</journal-id><journal-title-group><journal-title>Alzheimer's Research &#x00026; Therapy</journal-title></journal-title-group><issn pub-type="epub">1758-9193</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25452767</article-id><article-id pub-id-type="pmc">4248436</article-id><article-id pub-id-type="publisher-id">77</article-id><article-id pub-id-type="doi">10.1186/s13195-014-0077-y</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Evaluating the relationship between
amyloid-&#x003b2; and &#x003b1;-synuclein phosphorylated at Ser129 in dementia with Lewy bodies
and Parkinson&#x02019;s disease</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Swirski</surname><given-names>Marta</given-names></name><address><email>Marta.Swirski@bristol.ac.uk</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Miners</surname><given-names>J Scott</given-names></name><address><email>Scott.Miners@bristol.ac.uk</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>de Silva</surname><given-names>Rohan</given-names></name><address><email>r.desilva@ucl.ac.uk</email></address><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Lashley</surname><given-names>Tammaryn</given-names></name><address><email>t.lashley@ucl.ac.uk</email></address><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Ling</surname><given-names>Helen</given-names></name><address><email>h.ling@ucl.ac.uk</email></address><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Holton</surname><given-names>Janice</given-names></name><address><email>janice.holton@ucl.ac.uk</email></address><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Revesz</surname><given-names>Tamas</given-names></name><address><email>t.revesz@ucl.ac.uk</email></address><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Love</surname><given-names>Seth</given-names></name><address><email>seth.love@bris.ac.uk</email></address><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><label/>Dementia Research Group, Institute of Clinical
Neurosciences, School of Clinical Sciences, University of Bristol, Bristol, UK </aff><aff id="Aff2"><label/>Department of Molecular Neuroscience, Reta Lila Weston
Institute of Neurological Studies and Queen Square Brain Bank for
Neurological Disorders, Institute of Neurology, University College London, London, UK </aff></contrib-group><pub-date pub-type="epub"><day>1</day><month>12</month><year>2014</year></pub-date><pub-date pub-type="pmc-release"><day>1</day><month>12</month><year>2014</year></pub-date><pub-date pub-type="collection"><year>2014</year></pub-date><volume>6</volume><issue>9-9</issue><elocation-id>77</elocation-id><history><date date-type="received"><day>26</day><month>4</month><year>2014</year></date><date date-type="accepted"><day>14</day><month>10</month><year>2014</year></date></history><permissions><copyright-statement>&#x000a9; Swirski et al.; licensee BioMed Central
Ltd. 2014</copyright-statement><license license-type="open-access"><license-p>This is an Open Access article distributed under the terms of
the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly
credited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article,
unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Introduction</title><p>Lewy body and Alzheimer-type pathologies often co-exist.
Several studies suggest a synergistic relationship between amyloid-&#x003b2; (A&#x003b2;)
and &#x003b1;-synuclein (&#x003b1;-syn) accumulation. We have explored the relationship
between A&#x003b2; accumulation and the phosphorylation of &#x003b1;-syn at serine-129
(pSer129 &#x003b1;-syn), in post-mortem human brain tissue and in SH-SY5Y
neuroblastoma cells transfected to overexpress human &#x003b1;-syn.</p></sec><sec><title>Methods</title><p>We measured levels of A&#x003b2;40, A&#x003b2;42, &#x003b1;-syn and pSer129 &#x003b1;-syn by
sandwich enzyme-linked immunosorbent assay, in soluble and insoluble
fractions of midfrontal, cingulate and parahippocampal cortex and
thalamus, from cases of Parkinson&#x02019;s disease (PD) with (PDD; n = 12) and
without dementia (PDND; n = 23), dementia with Lewy bodies (DLB; n = 10)
and age-matched controls (n = 17). We also examined the relationship of
these measurements to cognitive decline, as measured by time-to-dementia
and the mini-mental state examination (MMSE) score in the PD patients,
and to Braak tangle stage.</p></sec><sec><title>Results</title><p>In most brain regions, the concentration of insoluble
pSer129 &#x003b1;-syn correlated positively, and soluble pSer129 &#x003b1;-syn
negatively, with the levels of soluble and insoluble A&#x003b2;. Insoluble
pSer129 &#x003b1;-syn also correlated positively with Braak stage. In most
regions, the levels of insoluble and soluble A&#x003b2; and the proportion of
insoluble &#x003b1;-syn that was phosphorylated at Ser129 were significantly
higher in the PD and DLB groups than the controls, and higher in the PDD
and DLB groups than the PDND brains. In PD, the MMSE score correlated
negatively with the level of insoluble pSer129 &#x003b1;-syn. Exposure of SH-SY5Y
cells to aggregated A&#x003b2;42 significantly increased the proportion of &#x003b1;-syn
that was phosphorylated at Ser129 (aggregated A&#x003b2;40 exposure had a
smaller, non-significant effect).</p></sec><sec><title>Conclusions</title><p>Together, these data show that the concentration of pSer129
&#x003b1;-syn in brain tissue homogenates is directly related to the level of A&#x003b2;
and Braak tangle stage, and predicts cognitive status in Lewy body
diseases.</p></sec><sec><title>Electronic supplementary material</title><p>The online version of this article (doi:10.1186/s13195-014-0077-y) contains supplementary material, which is available to
authorized users.</p></sec></abstract><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2014</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p>Alzheimer&#x02019;s disease (AD), Parkinson&#x02019;s disease (PD) and
dementia with Lewy bodies (DLB) are the most common age-related
neurodegenerative diseases and together account for 80% to 90% of patients
with dementia [<xref ref-type="bibr" rid="CR1">1</xref>,<xref ref-type="bibr" rid="CR2">2</xref>]. The pathological hallmarks of AD are
extracellular accumulations of amyloid-&#x003b2; (A&#x003b2;) as plaques and intracellular
aggregates of hyperphosphorylated tau that form neurofibrillary tangles and
neuropil threads. The pathological hallmarks of PD and DLB are Lewy bodies
and Lewy neurites, composed of &#x003b1;-synuclein (&#x003b1;-syn) [<xref ref-type="bibr" rid="CR3">3</xref>-<xref ref-type="bibr" rid="CR5">5</xref>]. Although these defining abnormalities are
characteristic and distinct, many dementia cases have mixed pathology: a
large proportion of AD patients (&#x0003e;50%) has additional Lewy body pathology
in addition to plaques and tangles [<xref ref-type="bibr" rid="CR6">6</xref>-<xref ref-type="bibr" rid="CR16">16</xref>]. In
Parkinson&#x02019;s disease with dementia (PDD) and DLB approximately 40% of cases
have significant numbers of A&#x003b2; plaques and neurofibrillary tangles
[<xref ref-type="bibr" rid="CR17">17</xref>]. Patients with mixed
pathology tend to pursue a more aggressive disease course [<xref ref-type="bibr" rid="CR18">18</xref>], with more pronounced cognitive
dysfunction than in patients with pure AD [<xref ref-type="bibr" rid="CR19">19</xref>-<xref ref-type="bibr" rid="CR24">24</xref>].</p><p>In PD and DLB, the number of cortical &#x003b1;-syn aggregates is
significantly higher in patients who have A&#x003b2; plaques in the cortex
[<xref ref-type="bibr" rid="CR25">25</xref>,<xref ref-type="bibr" rid="CR26">26</xref>] and &#x003b1;-syn accumulates within some
plaque-associated dystrophic neurites [<xref ref-type="bibr" rid="CR27">27</xref>]. Transgenic mice expressing both A&#x003b2; and &#x003b1;-syn had more
Lewy body pathology and more severe deficits in learning and memory than did
mice expressing &#x003b1;-syn alone [<xref ref-type="bibr" rid="CR28">28</xref>]. These studies suggest a synergistic relationship between
A&#x003b2; and &#x003b1;-syn. However, the reasons for the frequent pathological overlap
between AD and Lewy body diseases are poorly understood. A recent
meta-analysis of genome-wide association studies of AD and PD did not detect
any gene loci that increased the risk of both diseases and concluded that
the pathological overlap is likely to result from processes downstream of
the susceptibility genes for the individual diseases [<xref ref-type="bibr" rid="CR29">29</xref>]. &#x003b1;-syn can induce the
hyperphosphorylation of tau through the activation of protein kinase A
[<xref ref-type="bibr" rid="CR30">30</xref>] and glycogen synthase
kinase 3&#x003b2; [<xref ref-type="bibr" rid="CR31">31</xref>,<xref ref-type="bibr" rid="CR32">32</xref>] and, thereby, promote the formation
of neurofibrillary tangles. However, it is noteworthy that the most frequent
form of pathological overlap between Lewy body diseases and AD is the
presence of increased numbers of A&#x003b2; plaques in PDD and DLB [<xref ref-type="bibr" rid="CR25">25</xref>,<xref ref-type="bibr" rid="CR33">33</xref>], with limited formation of tangles and the
interactions between &#x003b1;-syn and A&#x003b2; were, therefore, the primary focus of this
study.</p><p>The predominant modification of &#x003b1;-syn in Lewy body diseases is
phosphorylation at Ser129 [<xref ref-type="bibr" rid="CR34">34</xref>,<xref ref-type="bibr" rid="CR35">35</xref>].
Approximately 90% of &#x003b1;-syn within Lewy bodies and neurites is phosphorylated
at Ser129, compared to 4% in the normal brain [<xref ref-type="bibr" rid="CR35">35</xref>]. The precise role of &#x003b1;-syn
phosphorylation at Ser129 remains unclear: most [<xref ref-type="bibr" rid="CR36">36</xref>-<xref ref-type="bibr" rid="CR39">39</xref>], but not all, studies [<xref ref-type="bibr" rid="CR40">40</xref>-<xref ref-type="bibr" rid="CR42">42</xref>]
suggest that phosphorylation mediates the aggregation and neurotoxicity of
&#x003b1;-syn. Irrespective of whether these changes precede the development of Lewy
bodies or occur at a later stage, it is well established that pSer129 &#x003b1;-syn
levels correlate with disease severity [<xref ref-type="bibr" rid="CR43">43</xref>-<xref ref-type="bibr" rid="CR45">45</xref>]. Obi
<italic>et al</italic>. [<xref ref-type="bibr" rid="CR44">44</xref>] found, that in DLB cases with AD pathology, pSer129
&#x003b1;-syn levels correlated strongly with parenchymal A&#x003b2; load (as assessed by
immunohistochemistry). The aim of our study was to explore this relationship
further, in multiple regions of brain from Parkinson&#x02019;s disease without
dementia (PDND), PDD and DLB patients and age-matched controls, by measuring
the concentrations of the two major forms of soluble and insoluble A&#x003b2; (A&#x003b2;40,
A&#x003b2;42) by sandwich ELISA, as previously [<xref ref-type="bibr" rid="CR46">46</xref>-<xref ref-type="bibr" rid="CR49">49</xref>], and
of soluble and insoluble &#x003b1;-syn (both total and pSer129 &#x003b1;-syn) also by ELISA.
In PD patients we also analyzed the relationship between A&#x003b2;, total &#x003b1;-syn,
pSer129 &#x003b1;-syn and ante-mortem cognitive function, as indicated by
mini-mental state examination (MMSE) scores. Lastly, in SH-SY5Y cells that
stably expressed high levels of endogenous &#x003b1;-syn, we assessed the direct
influence of different forms of A&#x003b2; on the phosphorylation of &#x003b1;-syn at Ser129
<italic>in vitro</italic>.</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Methods</title><sec id="Sec3"><title>Case selection</title><p>We studied 35 cases of PD (23 PDND and 12 PDD) from the
Queen Square Brain Bank (QSBB) for Neurological Disorders, UCL Institute
of Neurology, London, and 10 cases of DLB and 17 age-matched controls
from the South West Dementia Brain Bank (SWDBB), University of Bristol
(Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). Protocols for brain
banking at the QSBB were approved by the London Multi-Centre Research
Ethics Committee (REC reference 08/H0718/54&#x02009;+&#x02009;5) and written consent for
the use of brain tissue and for access to the medical record for research
was obtained from all cases. The South West Dementia Brain Bank had
ethical approval from the North Somerset and South Bristol Research
Ethics Committee (REC reference 08/H0106/28).<table-wrap id="Tab1"><label>Table 1</label><caption><p>
<bold>Control, Parkinson&#x02019;s disease
non-dementia (PDND), Parkinson&#x02019;s disease dementia (PDD)
and dementia with Lewy bodies (DLB) cases: demographic and
clinical data</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th/><th>
<bold>Control (n = 17)</bold>
</th><th>
<bold>PDND (n = 23)</bold>
</th><th>
<bold>PDD (n = 12)</bold>
</th><th>
<bold>DLB (n = 10)</bold>
</th></tr></thead><tbody><tr valign="top"><td>Mean age at onset (years)&#x02009;&#x000b1;&#x02009;SD</td><td>N/A</td><td>61.1&#x02009;&#x000b1;&#x02009;9.1</td><td>58.2&#x02009;&#x000b1;&#x02009;7.7</td><td>69.7&#x02009;&#x000b1;&#x02009;7.3</td></tr><tr valign="top"><td>Mean age at death (years)&#x02009;&#x000b1;&#x02009;SD</td><td>79.2&#x02009;&#x000b1;&#x02009;8.7</td><td>77.7&#x02009;&#x000b1;&#x02009;6.2</td><td>77.85&#x02009;&#x000b1;&#x02009;6.1</td><td>77.0&#x02009;&#x000b1;&#x02009;9.0</td></tr><tr valign="top"><td>Mean disease duration
(years)&#x02009;&#x000b1;&#x02009;SD</td><td>N/A</td><td>16.6&#x02009;&#x000b1;&#x02009;6.7</td><td>19.7&#x02009;&#x000b1;&#x02009;6.5</td><td>7.3&#x02009;&#x000b1;&#x02009;2.0</td></tr><tr valign="top"><td>Gender (%)</td><td>3 (18) female</td><td>13 (57) female</td><td>6 (50) female</td><td>4 (40) female</td></tr><tr valign="top"><td>Mean post-mortem delay
(hours)&#x02009;&#x000b1;&#x02009;SD</td><td>37.0&#x02009;&#x000b1;&#x02009;16.6</td><td>63.6&#x02009;&#x000b1;&#x02009;27.0</td><td>38.2&#x02009;&#x000b1;&#x02009;21.7</td><td>28.0&#x02009;&#x000b1;&#x02009;10.9</td></tr><tr valign="top"><td>Mean time to dementia
(years)&#x02009;&#x000b1;&#x02009;SD</td><td>N/A</td><td>N/A</td><td>14.6&#x02009;&#x000b1;&#x02009;6.9</td><td>N/A</td></tr><tr valign="top"><td>Median Braak tangle stage (range)</td><td>II (0 to III)</td><td>II (I to IV)</td><td>II (I to IV)</td><td>II (0 to III)</td></tr></tbody></table><table-wrap-foot><p>N/A, not available; n, number; SD, standard
deviation.</p></table-wrap-foot></table-wrap></p><p>All disease cases were diagnosed using widely accepted
neuropathological criteria [<xref ref-type="bibr" rid="CR50">50</xref>,<xref ref-type="bibr" rid="CR51">51</xref>].
Cases were excluded from the study if they had a neuropathological
diagnosis of AD (that is, if histology showed AD neuropathological change
that was considered a sufficient explanation for dementia according to
the National Institute on Aging-Alzheimer&#x02019;s Association guidelines for
the neuropathological assessment of AD [<xref ref-type="bibr" rid="CR51">51</xref>] or any other neurodegenerative disease apart from
PD or DLB. They were also excluded if neurohistology revealed severe
cerebral amyloid angiopathy or other significant cerebrovascular
disease.</p><p>To assess the possible influence of A&#x003b2;-induced
phosphorylation of &#x003b1;-syn on cognitive decline in PD patients, our
analyses included the time to dementia in patients with PDD, and the
score on the MMSE within the last year of life, where available.</p><p>In all cases consent had been given for the use of brain
tissue and for access to the patients&#x02019; clinical records for
research.</p></sec><sec id="Sec4"><title>Tissue preparation</title><p>Brain tissue (200&#x000a0;mg) samples of midfrontal, cingulate and
parahippocampal cortex and thalamus were sequentially extracted in 1%
NP-40 buffer (140&#x000a0;mM NaCl, 3&#x000a0;mM KCl, 25&#x000a0;mM TRIS, 5&#x000a0;mM
ethylenediaminetetraacetic acid (EDTA), 2&#x000a0;mM 1,10 phenanthroline) as
previously described for A&#x003b2; measurements in human post-mortem tissue
[<xref ref-type="bibr" rid="CR46">46</xref>,<xref ref-type="bibr" rid="CR48">48</xref>,<xref ref-type="bibr" rid="CR49">49</xref>,<xref ref-type="bibr" rid="CR52">52</xref>].
The tissue was homogenized in a Precellys 24 homogenizer (Stretton
Scientific, Derbyshire, UK) with 2.3&#x000a0;mm ceramic beads (Biospec, Stratech,
Suffolk, UK). The homogenates were spun at 13,000&#x02009;&#x000d7;&#x02009;g for 15&#x000a0;minutes at
4&#x000b0;C and the supernatant was removed and stored at &#x02212;80&#x000b0;C. Insoluble
material was solubilized by vigorous agitation in 6&#x000a0;M GuHCl,
re-homogenized and left for four hours at room temperature (RT) before
storage at &#x02212;80&#x000b0;C.</p></sec><sec id="Sec5"><title>Total &#x003b1;-syn sandwich ELISA</title><p>Total &#x003b1;-syn level was determined by sandwich ELISA. Mouse
monoclonal anti-&#x003b1;-syn antibody (0.5&#x000a0;&#x003bc;g/ml; BD Biosciences, Oxford, UK)
was coated onto a NUNC Maxisorp 96-well plate overnight at RT. The plate
was washed in PBS/0.01% tween-20 and blocked for 1.5&#x000a0;hours in 1% BSA/PBS.
Tissue samples (insoluble and soluble extracts diluted 1:200 in PBS) were
added for two hours at RT with constant shaking. The plate was rinsed,
tapped dry and biotinylated polyclonal anti-&#x003b1;-synuclein (1&#x000a0;&#x003bc;g/ml; R&#x00026;D
Systems, Oxford, UK) diluted in PBS was added for two hours at RT. The
plate was rinsed and tapped dry, streptavidin-horseradish peroxidase
(HRP) (1:200, R&#x00026;D Systems) was added for 20&#x000a0;minutes and, after
further washing, chromogenic substrate (TMBS, R&#x00026;D Systems) was added
for 20&#x000a0;minutes in the dark. The reaction was stopped with 2&#x000a0;N sulfuric
acid and absorbance at 450 nM read in a FLUOstar Optima plate reader (BMG
Labtech, Aylesbury, UK). Total &#x003b1;-syn levels were interpolated from
measurements made on serial dilutions of recombinant human &#x003b1;-syn ranging
from 62.5 to 0.98&#x000a0;ng/ml (rPeptide, Stratech, Suffolk, UK). Measurements
for each sample were repeated in duplicate.</p></sec><sec id="Sec6"><title>pSer129 &#x003b1;-syn sandwich ELISA</title><p>Mouse monoclonal anti-&#x003b1;-syn antibody (0.5&#x000a0;&#x003bc;g/ml; BD
Biosciences) was coated onto a NUNC Maxisorp 96-well plate overnight at
RT. The plate was washed in PBS/0.01% tween-20 and blocked for two hours
in 1% BSA/PBS. Tissue samples (insoluble extracts diluted 1:99 in PBS,
soluble extracts diluted 1:3) were added for five hours at RT with
constant shaking. The plate was rinsed and tapped dry and anti-pSer129
&#x003b1;-syn (0.8&#x000a0;&#x003bc;g/ml; Abcam, Cambridge, UK) diluted in PBS was added and left
to incubate at 4&#x000b0;C overnight. Following washing of the plate,
biotinylated horse anti-rabbit antibody (1.5&#x000a0;&#x003bc;g/ml; Vector labs,
Peterborough, UK) diluted in PBS with 0.01% tween-20 was added for one
hour at RT. The plate was rinsed and tapped dry, streptavidin-HRP was
added for one hour followed by chromogenic substrate for 20&#x000a0;minutes in
the dark. The reaction was stopped with 2&#x000a0;N sulfuric acid and absorbance
at 450 nM read in a FLUOstar Optima plate reader (BMG Labtech). The
concentration of pSer129 &#x003b1;-syn was determined as described previously
[<xref ref-type="bibr" rid="CR53">53</xref>], by interpolation
from measurements of serial dilutions (200 to 3.125&#x000a0;ng/ml) of recombinant
&#x003b1;-syn that had been phosphorylated at Ser129 by incubating with casein
kinase II (see below).</p></sec><sec id="Sec7"><title>Specificity of the pSer129 &#x003b1;-syn antibody</title><p>We conducted a preliminary study to confirm the specificity
of the pSer129 &#x003b1;-syn antibody. Full-length recombinant human &#x003b1;-syn
(1&#x000a0;mg/ml; rPeptide, Statech) was incubated with casein kinase I (CKI)
(1,000 units, New England Biolabs, Hitchin, UK) or casein kinase II
(CKII) (500 units, New England Biolabs, one unit being defined as the
amount of CKII required to catalyze the transfer of 1 &#x003c1;mol of phosphate
to 100&#x000a0;&#x003bc;M CKII peptide sequence RRRADSDDDDD in one minute at 30&#x000b0;C) for
one hour at 30&#x000b0;C in the presence of 200&#x000a0;&#x003bc;M ATP (New England Biolabs)
(protocol adapted from Lee <italic>et al</italic>.
[<xref ref-type="bibr" rid="CR54">54</xref>]; Walker <italic>et al</italic>. [<xref ref-type="bibr" rid="CR45">45</xref>]). As a control, another sample was treated in the
same manner in the absence of either CKI or CKII. Samples were diluted in
1% Tris-buffered saline (TBS) (1:400) and applied to a pre-wetted (in 1%
TBS) nitrocellulose membrane and incubated at room temperature for one
hour. The membrane was washed in 0.3% Tris-buffered saline with Tween 20
(TBST) then incubated with 10% non-fat milk in 0.3% TBST for one hour at
RT with agitation to prevent non-specific binding. After washing the
membrane in TBST, primary antibodies (total &#x003b1;-syn, 0.5&#x000a0;&#x003bc;g/ml, BD
Biosciences; pSer129 &#x003b1;-syn, 0.8&#x000a0;&#x003bc;g/ml, Abcam; pSer87 &#x003b1;-syn, 200&#x000a0;&#x003bc;g/ml,
Santa Cruz, Dallas, TX, USA) diluted in 5% non-fat milk in TBST were
applied overnight. The following day the membrane was again washed in
TBST and incubated with peroxidase-conjugated secondary antibody diluted
in 5% non-fat milk in TBST for one hour at RT with agitation. The
membrane was washed and then developed on photographic film using
Immobilon&#x02122;chemiluminescence reagents (Millipore, Danvers, MA, USA)
according to the manufacturer&#x02019;s guidelines.</p><p>The pSer129 &#x003b1;-syn antibody labelled &#x003b1;-syn following
incubation with CKII, and to a lesser extent CKI, but did not label
recombinant &#x003b1;-syn that had not been phosphorylated with CKI or CKII. In
contrast, a non-phosphorylation-specific &#x003b1;-syn antibody (BD Biosciences)
detected all forms of &#x003b1;-syn, and a pSer87-specific &#x003b1;-syn antibody
detected a signal only after incubation of &#x003b1;-syn with CKI (as expected
from previous studies by Okochi <italic>et al</italic>.
[<xref ref-type="bibr" rid="CR55">55</xref>] and Paleologou
<italic>et al</italic>. [<xref ref-type="bibr" rid="CR40">40</xref>]). These findings confirmed the
specificity of the pSer129 &#x003b1;-syn antibody (see Additional file
<xref rid="MOESM1" ref-type="media">1</xref>: Figure S1).</p></sec><sec id="Sec8"><title>A&#x003b2;40 sandwich ELISA</title><p>The level of A&#x003b2;40 was measured in post-mortem brain tissue
samples by sandwich ELISA as described [<xref ref-type="bibr" rid="CR49">49</xref>,<xref ref-type="bibr" rid="CR56">56</xref>].
High-binding Costar 96-well plates (R&#x00026;D Systems) were coated with
anti-human A&#x003b2; (2&#x000a0;&#x003bc;g/ml; clone 6E10, raised against amino acids 4&#x02013;7,
Covance, Maidenhead, UK) diluted in PBS and incubated overnight at RT.
After five washes with PBS containing 0.05% tween-20, the plates were
blocked with 300&#x000a0;&#x003bc;L protein-free PBS blocking buffer (Thermo Fisher
Scientific, Loughborough, UK) for two hours at RT. After a further five
washes, brain homogenate samples (insoluble extracts diluted 1:49,
soluble extracts diluted 1:3) and serial dilutions of recombinant human
A&#x003b2;1-40 (Sigma Aldrich, Dorset, UK) in PBS containing 1% 1,10
phenanthroline (Sigma Aldrich) (to prevent degradation of A&#x003b2;
[<xref ref-type="bibr" rid="CR57">57</xref>]) were incubated for
two hours at RT with rocking. After a further wash step, the plates were
incubated with anti-human A&#x003b2;1-40 (1&#x000a0;&#x003bc;g/ml; Covance) for two hours at RT.
The antibody was prepared using the Lightning-Link biotinylation kit
(Innova Biosciences, Cambridge, UK) according to the manufacturer&#x02019;s
guidelines. After further washes, the plate was rinsed and tapped dry,
streptavidin-HRP added for 20&#x000a0;minutes, and chromogenic substrate for
20&#x000a0;minutes in the dark. The reaction was stopped with 2&#x000a0;N sulfuric acid
and absorbance at 450 nM read in a FLUOstar Optima plate reader (BMG
Labtech). The A&#x003b2;1&#x02013;40 level in the brain tissue samples was interpolated
from a standard curve generated by serial dilution of recombinant human
A&#x003b2;1&#x02013;40 (Sigma Aldrich) in the range 16,000 to 1.024 nM. Each sample was
assayed in duplicate.</p></sec><sec id="Sec9"><title>A&#x003b2;42 sandwich ELISA</title><p>The level of A&#x003b2;42 was measured in post-mortem brain tissue
samples by sandwich ELISA as outlined above with a few modifications.
Anti-human A&#x003b2;1-42 (0.5&#x000a0;&#x003bc;g/ml; 12&#x000a0;F4, Covance) was used as the capture
antibody. Tissue samples (insoluble extracts diluted 1:9, soluble
extracts diluted 1:3) were incubated at RT for four hours. Biotinylated
anti-human A&#x003b2; (0.1&#x000a0;&#x003bc;g/ml; Thermo Fisher Scientific) diluted in PBS was
used for detection and incubated overnight at 4&#x000b0;C. Following washing,
rinsing and drying, streptavidin-HRP was added to the plate for one hour
and chromogenic substrate for 20&#x000a0;minutes in the dark. A&#x003b2;1-42
concentration in brain tissue was interpolated from a standard curve
generated by serial dilution (16,000 to 1.024 nM) of recombinant human
A&#x003b2;1&#x02013;42 (Sigma Aldrich). Each sample was assayed in duplicate. The A&#x003b2;1-42
ELISA did not detect A&#x003b2;1-40, and the A&#x003b2;1-40 ELISA did not detect
A&#x003b2;1-42.</p></sec><sec id="Sec10"><title>Sandwich ELISA validation</title><p>Intra-assay and inter-assay coefficients of variation were
calculated for the ELISAs as well as spike and recovery tests (see
Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Table S3),
in which serial dilutions of A&#x003b2;40, A&#x003b2;42, &#x003b1;-syn or pSer129 &#x003b1;-syn were
added to brain homogenates rather than assay diluent. The recovered:added
ratio for each added protein (a ratio sometimes termed the response rate)
and the correlation between the calculated concentration and measured
concentration of added protein were assessed in the insoluble and soluble
fractions of the homogenates. The recovered:added ratios of soluble and
insoluble pSer129 &#x003b1;-syn (the former well below 1, the latter well above
1) suggests that on addition to brain homogenates, which already
contained relatively high baseline amounts of &#x003b1;-syn as well as some
pSer129 &#x003b1;-syn, most of the added soluble pSer129 &#x003b1;-syn rapidly aggregated
and entered the insoluble fraction in the homogenate. Data from the total
&#x003b1;-syn and A&#x003b2;42 assays indicated a good recovery rate, with recovery of
A&#x003b2;40 being 50%. In all of the assays there was a very close linear
correlation between the concentration of added protein and the
concentration of protein determined by the assay (as shown by the Pearson
r and <italic>P</italic> values), enabling valid
comparisons to be made between brains and also between cohorts.</p></sec><sec id="Sec11"><title>Immunohistochemical assessment of &#x003b1;-syn, pSer129 &#x003b1;-syn, A&#x003b2;42 and
A&#x003b2;40</title><p>Formalin-fixed paraffin-embedded sections of mid-frontal,
cingulate, parahippocampal cortex and thalamus in all DLB cases were
immunolabelled for A&#x003b2;1-42 (0.5&#x000a0;&#x003bc;g/ml; Covance), A&#x003b2;1-40 (1&#x000a0;&#x003bc;g/ml;
Covance), pSer129 &#x003b1;-syn (0.8&#x000a0;&#x003bc;g/ml; Abcam) and &#x003b1;-syn (80&#x000a0;mg/l; Vector
Labs, Peterborough, UK) by use of a standard streptavidin-biotin-HRP
immunohistochemistry protocol [<xref ref-type="bibr" rid="CR58">58</xref>]. The extent of immunolabelling of each antigen was
measured by field fraction analysis with the help of Image Pro Plus&#x02122;
software (Media Cybernetics, Marlow, UK) driving a Leica DM microscope
with a motorized stage. The software made an unbiased selection of
twelve&#x02009;&#x000d7;&#x02009;20-objective fields and the percentage area immunopositive for
the relevant antigen was determined for each section, as outlined
previously [<xref ref-type="bibr" rid="CR59">59</xref>,<xref ref-type="bibr" rid="CR60">60</xref>].</p></sec><sec id="Sec12"><title>Cell culture</title><p>SH-SY5Y neuroblastoma cells were transfected with a
pCDNA3.1 vector (Life Technologies, UK) containing wild-type human
<italic>SNCA</italic> cDNA under the control of a
cytomegalovirus (CMV) promoter. Transfection was carried out with
TransFast (Promega, Southampton, UK), followed by selection of clones
(and their subsequent maintenance) in culture medium containing
0.3&#x000a0;mg/ml&#x000a0;G418 (Geneticin, Life Technologies, Paisley, UK). The culture
medium for SH-SY5Y cells, either untransfected or stably expressing human
wild-type &#x003b1;-syn, consisted of 42% vol/vol Ham&#x02019;s F12 nutrient mixture
(F12) (Sigma) and 42% vol/vol Eagle&#x02019;s minimum essential medium (Sigma),
supplemented with 15% vol/vol fetal calf serum (Sigma), 2&#x000a0;mM&#x000a0;L-glutamine
(Sigma), 1% vol/vol non-essential amino acids solution (Sigma), 20
units/mL penicillin, 20&#x000a0;mg/mL streptomycin (Sigma) and 250&#x000a0;ng/mL
amphotericin B (Life Technologies) at 37&#x000b0;C in 5%
CO<sub>2</sub> (21% O<sub>2</sub>).</p></sec><sec id="Sec13"><title>Addition of A&#x003b2; to cell cultures</title><p>Before treatment with A&#x003b2;, the culture medium was replaced
with serum-free medium (no fetal bovine serum and no G418) for 24 hous.
A&#x003b2; solutions were also prepared 24&#x000a0;hours in advance. Stock solutions of
1&#x000a0;mM A&#x003b2;42 and A&#x003b2;40 (Cambridge Biosciences, Cambridge, UK) in 35%
acetonitrile were diluted in serum-free medium at 1&#x000a0;&#x003bc;M and 10&#x000a0;&#x003bc;M. The A&#x003b2;
was either left overnight to aggregate at 26&#x000b0;C for 24&#x000a0;hours (as
previously described [<xref ref-type="bibr" rid="CR61">61</xref>])
or immediately placed overnight in a &#x02212;80&#x000b0;C freezer. A&#x003b2; (either aggregated
or fresh) was added to flasks the following day (10&#x000a0;&#x003bc;M acetonitrile was
added to control flasks) and incubated for 24&#x000a0;hours.</p></sec><sec id="Sec14"><title>Preparation of cell lysates for sandwich ELISA</title><p>Cells were incubated with Dulbecco&#x02019;s PBS without calcium
chloride and magnesium chloride (Sigma-Aldrich) at 37&#x000b0;C for five minutes
and then removed from the flask, transferred into a Falcon tube, and spun
for three minutes at 13,000&#x000a0;rpm. The cells were washed in PBS and lysed
in 100&#x000a0;&#x003bc;l non-denaturing proprietary cell lysis buffer (Sigma-Aldrich,
Dorset, UK) according to the manufacturer&#x02019;s guidelines, and spun at
13,000&#x000a0;rpm for 15&#x000a0;minutes at 4&#x000b0;C. Cell supernatants (soluble fraction)
were removed and stored at &#x02212;80&#x000b0;C until used. A total of 6&#x000a0;M GuHCl
(100&#x000a0;&#x003bc;l) was added to the remaining insoluble pellet and left at RT for
1.5&#x000a0;hours (insoluble fraction) before the tube was stored at
&#x02212;80&#x000b0;C.</p></sec><sec id="Sec15"><title>Statistical analysis</title><p>Whenever possible, parametric statistical tests were used
for comparisons between groups (in some cases this required logarithmic
transformation of the data to obtain a normal distribution): analysis of
variance (ANOVA) with Dunnett&#x02019;s test for pairwise intergroup comparisons,
or repeated measures ANOVA for the analysis of <italic>in
vitro</italic> measurements on cells exposed to different
concentrations of A&#x003b2; during the same experiment. For variables that were
not normally distributed even after transformation, the Kruskall-Wallis
test was used, with Dunn&#x02019;s test for pairwise intergroup comparisons.
Pearson or Spearman analysis was used as appropriate to assess the
correlation between pairs of variables. Statistical tests were performed
using GraphPad Prism v5. <italic>P</italic>-values
&#x0003c;0.05 were considered statistically significant.</p></sec></sec><sec id="Sec16" sec-type="results"><title>Results</title><sec id="Sec17"><title>pSer129 &#x003b1;-syn correlates with insoluble and soluble A&#x003b2;</title><p>In most regions the level of insoluble pSer129 &#x003b1;-syn
increased as the levels of A&#x003b2;40 and A&#x003b2;42 increased (Figure&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>, Additional file <xref rid="MOESM3" ref-type="media">3</xref>: Table S1), with significant positive
correlations between insoluble pSer129 &#x003b1;-syn and soluble A&#x003b2;40 and A&#x003b2;42 in
the parahippocampal cortex (soluble A&#x003b2;40: r = 0.376, <italic>P</italic> = 0.003; soluble A&#x003b2;42: r = 0.287, <italic>P</italic> = 0.024) and thalamus (soluble A&#x003b2;40: r =
0.398, <italic>P</italic> = 0.002; soluble A&#x003b2;42: r =
0.404, <italic>P</italic> = 0.002). Significant
positive correlations were also found between insoluble pSer129 &#x003b1;-syn and
insoluble A&#x003b2;42 in the cingulate (r = 0.293, <italic>P</italic> = 0.022) and parahippocampal cortex (r = 0.314,
<italic>P</italic> = 0.013) as well as between
insoluble pSer129 &#x003b1;-syn and insoluble A&#x003b2;40 in the midfrontal (r = 0.719,
<italic>P</italic> &#x0003c;0.0001) and cingulate cortex
(r = 0.304, <italic>P</italic> = 0.017). Significant
negative correlations between soluble pSer129 &#x003b1;-syn and soluble A&#x003b2;42 were
found in the cingulate cortex and thalamus (Figure&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>; Additional file <xref rid="MOESM3" ref-type="media">3</xref>: Table S1) (cingulate cortex:
r&#x02009;=&#x02009;&#x02212;0.287, <italic>P</italic> = 0.035; thalamus:
r&#x02009;=&#x02009;&#x02212;0.373, <italic>P</italic> = 0.0036). In contrast,
a significant positive correlation was observed between soluble A&#x003b2;42 and
soluble pSer129 &#x003b1;-syn in the midfrontal cortex (r = 0.443, <italic>P</italic> = 0.0015). Significant negative
correlations between soluble A&#x003b2;40 and soluble pSer129 &#x003b1;-syn were found in
three of four regions (cingulate cortex: r&#x02009;=&#x02009;&#x02212;0.313, <italic>P</italic> = 0.021; parahippocampal cortex:
r&#x02009;=&#x02009;&#x02212;0.286, P = 0.028; and thalamus: r&#x02009;=&#x02009;&#x02212;0.376, <italic>P</italic> = 0.0033). Significant negative correlations were also
found between soluble pSer129 &#x003b1;-syn and insoluble A&#x003b2;42 in the midfrontal
cortex and thalamus (midfrontal cortex: r&#x02009;=&#x02009;&#x02212;0.475, <italic>P</italic> = 0.0005; thalamus: r&#x02009;=&#x02009;&#x02212;0.399, <italic>P</italic> = 0.0018). A significant positive
correlation between soluble pSer129 &#x003b1;-syn and insoluble A&#x003b2;40 was also
found in the parahippocampus (r = 0.316, <italic>P</italic> = 0.015).<fig id="Fig1"><label>Figure 1</label><caption><p>
<bold>Correlation between A&#x003b2; and insoluble
pSer129 &#x003b1;-syn.</bold> Each point represents a separate
case. The best-fit linear regression (solid lines) and 95%
confidence intervals (interrupted lines) are superimposed.
Only significant <italic>P</italic>-values
(and associated correlation coefficients) are shown in the
figure. Significant positive correlations between insoluble
pSer129 &#x003b1;-syn and soluble A&#x003b2;42/A&#x003b2;40 were found in the
parahippocampal (PH) cortex and thalamus (TH). Significant
positive correlations were also found between insoluble
pSer129 &#x003b1;-syn and insoluble A&#x003b2;42 in the cingulate (CG) and PH
cortex. In addition, significant correlations were found
between insoluble pSer129 &#x003b1;-syn and insoluble A&#x003b2;40 in the
midfrontal and CG cortex. A&#x003b2;, amyloid-&#x003b2;; pSer129 &#x003b1;-syn,
alpha-synuclein phosphorylated at serine 129.</p></caption><graphic xlink:href="13195_2014_77_Fig1_HTML" id="MO1"/></fig><fig id="Fig2"><label>Figure 2</label><caption><p>
<bold>Correlation between A&#x003b2; and soluble
pSer129 &#x003b1;-syn.</bold> Each point represents a separate
case. The best-fit linear regression (solid lines) and 95%
confidence intervals (interrupted lines) are superimposed.
Only significant <italic>P</italic>-values
(and associated correlation coefficients) are shown in the
figure. Significant negative correlations between soluble
A&#x003b2;42 and soluble pSer129 &#x003b1;-syn were found in the cingulate
(CG) cortex and thalamus (TH). In contrast, a significant
positive correlation was found between soluble A&#x003b2;42 and
soluble pSer129 &#x003b1;-syn in the midfrontal (MF) cortex.
Significant negative correlations were found between soluble
A&#x003b2;40 and soluble pSer129 &#x003b1;-syn in the CG, parahippocampal
(PH) cortex and TH. Significant negative correlations were
also found between soluble pSer129 &#x003b1;-syn and insoluble A&#x003b2;42
in the MF cortex and TH. A significant positive correlation
was observed between soluble pSer129 &#x003b1;-syn and insoluble A&#x003b2;40
in the PH cortex. A&#x003b2;, amyloid-&#x003b2;; pSer129 &#x003b1;-syn,
alpha-synuclein phosphorylated at serine 129.</p></caption><graphic xlink:href="13195_2014_77_Fig2_HTML" id="MO2"/></fig></p><p>Field fraction analysis of the extent of
immunohistochemical labeling of these antigens in the DLB cases revealed
a significant positive correlation between pSer129 &#x003b1;-syn and A&#x003b2;42 in the
mid-frontal region only (r = 0.849, <italic>P</italic>
= 0.0019) (see Additional file <xref rid="MOESM4" ref-type="media">4</xref>: Table S2). There was only weak, non-significant
correlation between the level of these antigens in the brain homogenates
and the percentage area labeled in paraffin sections from the
corresponding regions in the contralateral cerebral hemisphere.</p></sec><sec id="Sec18"><title>Insoluble pSer129 &#x003b1;-syn level correlates with Braak tangle
stage</title><p>The insoluble pSer129 &#x003b1;-syn level correlated positively
with the Braak tangle stage only in the mid-frontal cortex
(Figure&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>) (r = 0.526,
<italic>P</italic> = 0.0002). Soluble pSer129 &#x003b1;-syn
levels correlated negatively with the Braak stage in the cingulate region
only (r&#x02009;=&#x02009;&#x02212;0.335, <italic>P</italic> = 0.028).<fig id="Fig3"><label>Figure 3</label><caption><p>
<bold>Correlation between pSer129 &#x003b1;-syn and
Braak stage in combined PD (n = 35) and DLB (n = 10)
patients.</bold> Each point represents a separate
case. The best-fit linear regression (solid lines) and 95%
confidence intervals (interrupted lines) are superimposed.
Only significant <italic>P</italic>-values
(and associated correlation coefficients) are shown in the
figure. Insoluble pSer129 &#x003b1;-syn level correlated positively
with Braak stage in the midfrontal cortex. Soluble pSer129
&#x003b1;-syn level correlated negatively with Braak stage in the
cingulate cortex. DLB, dementia wth Lewy bodes; PD,
Parkinson&#x02019;s disease; pSer129 &#x003b1;-syn, alpha-synuclein
phosphorylated at serine 129.</p></caption><graphic xlink:href="13195_2014_77_Fig3_HTML" id="MO3"/></fig></p></sec><sec id="Sec19"><title>Insoluble A&#x003b2; is higher in disease groups than controls and in DLB
than PD in most regions</title><p>The level of insoluble A&#x003b2;42 in the cingulate and
parahippocampal cortex was significantly higher in all disease cohorts
than controls (Figure&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>). The DLB
cohort had a significantly higher level of insoluble A&#x003b2;42 in the
midfrontal cortex than did any of the other groups. In contrast, the
level of insoluble A&#x003b2;42 in the thalamus was higher in the PD cohorts than
in DLB or controls.<fig id="Fig4"><label>Figure 4</label><caption><p>
<bold>Insoluble A&#x003b2; and &#x003b1;-syn levels in
controls, PDND, PDD and DLB.</bold> Box-and-whisker
plots indicate the full range, interquartile range and median
value in each group. Insoluble A&#x003b2;<sub>42</sub>
level was significantly higher in DLB than controls in all
regions except the thalamus. It was also significantly higher
in DLB than PDND or PDD in the midfrontal region but lower in
the thalamus. In all regions except the midfrontal, the
insoluble A&#x003b2;42 level was significantly higher in both PDND
and PDD than controls. The insoluble A&#x003b2;40 level was
significantly greater in midfrontal and cingulate cortex and
thalamus in PDND, PDD and DLB than controls, and in the
parahippocampus the level was significantly higher in DLB
than in PDND or PDD but not controls. The total insoluble
&#x003b1;-syn level was significantly higher in PDD than controls or
PDND in midfrontal cortex and higher than in DLB or controls
in the parahippocampus. Total insoluble &#x003b1;-syn in the
cingulate cortex was significantly higher in DLB than in PDND
or controls. No significant differences between groups were
observed in the thalamus. A&#x003b2;, amyloid-&#x003b2;; DLB, dementia with
Lewy bodies; PDD, Parkinson&#x02019;s disease with dementia; PDND,
Parkinson&#x02019;s disease without dementia; &#x003b1;-syn,
&#x003b1;-synuclein.</p></caption><graphic xlink:href="13195_2014_77_Fig4_HTML" id="MO4"/></fig></p><p>Similar results were observed for insoluble A&#x003b2;40, with some
regional differences. In the midfrontal and cingulate cortex it was
present at a significantly higher level in all disease groups than
controls. The level of insoluble A&#x003b2;40 in the parahippocampus was
significantly higher in DLB than controls.</p></sec><sec id="Sec20"><title>Soluble A&#x003b2; is higher in disease groups than controls and in
dementia groups than PDND in several regions</title><p>The level of soluble A&#x003b2;42 was significantly higher in the
PD cohorts than controls in all regions (Figure&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>). The level in the parahippocampal cortex was
significantly higher in DLB than PDND or controls, and in the midfrontal
and cingulate cortex it was higher in PDD than DLB. All disease groups
had a significantly higher level of soluble A&#x003b2;40 than controls in most
regions.<fig id="Fig5"><label>Figure 5</label><caption><p>
<bold>Soluble A&#x003b2; and &#x003b1;-syn levels in
controls, PDND, PDD and DLB.</bold> Box-and-whisker
plots indicate the full range, interquartile range and median
value in each group. Soluble A&#x003b2;42 level was significantly
higher in PDND and PDD than controls in all regions, and in
the midfrontal and cingulate cortex, it was significantly
higher in PDD than DLB. In DLB the level of soluble A&#x003b2;42 was
significantly higher than in controls and PDND in the
parahippocampus and higher than controls in the thalamus. The
soluble A&#x003b2;40 level was significantly elevated in PDND and PDD
compared with controls in all regions. The level was also
significantly higher in DLB than in controls in all regions
except the cingulate cortex. Soluble total &#x003b1;-syn levels were
significantly greater in PDND than controls in all regions,
and significantly higher in PDD than controls in the
midfrontal cortex, parahippocampus and thalamus. *<italic>P</italic> &#x0003c;0.05, **<italic>P</italic> &#x0003c;0.01, ***<italic>P</italic> &#x0003c;0.001. A&#x003b2;, amyloid-&#x003b2;; DLB,
dementia with Lewy bodies; PDD, Parkinson&#x02019;s disease with
dementia; PDND, Parkinson&#x02019;s disease without dementia; &#x003b1;-syn,
&#x003b1;-synuclein.</p></caption><graphic xlink:href="13195_2014_77_Fig5_HTML" id="MO5"/></fig></p></sec><sec id="Sec21"><title>Total insoluble &#x003b1;-syn varies modestly between disease
groups</title><p>The level of insoluble &#x003b1;-syn in the midfrontal and
parahippocampal cortex (Figure&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>)
was significantly higher in PDD than in PDND or controls whereas in the
DLB cohort the level was significantly higher in the cingulate region
only. No significant differences were found between groups in the
thalamus. No significant differences between controls and PDND were found
in any region.</p></sec><sec id="Sec22"><title>Total soluble &#x003b1;-syn is higher in PD than controls but lower in DLB
than PD</title><p>The level of soluble &#x003b1;-syn (Figure&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>) was significantly higher in PDND than
controls in all regions, and in PDD than controls in the midfrontal and
parahippocampal cortex and thalamus. Unexpectedly, the DLB cohort had
significantly lower soluble total &#x003b1;-syn than the PD groups in most
regions.</p></sec><sec id="Sec23"><title>Insoluble pSer129 &#x003b1;-syn is higher and soluble pSer129 &#x003b1;-syn is
lower in disease groups than controls</title><p>In most regions, the proportion of insoluble &#x003b1;-syn that was
phosphorylated at Ser129 was significantly higher in the PDD and DLB
groups than the controls (Figure&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>) and in several regions the proportion was
significantly higher in both PDD and DLB than PDND. Conversely, in the
soluble fraction, the proportion of &#x003b1;-syn that was phosphorylated at
Ser129 was significantly higher in controls than disease groups in most
regions (Figure&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>). Irrespective
of cohort, a significantly higher proportion of &#x003b1;-syn was phosphorylated
at Ser129 in the insoluble than the soluble fractions (data not shown;
<italic>P</italic> &#x0003c;0.001). Absolute protein
levels of pSer129 &#x003b1;-syn are displayed in Additional file <xref rid="MOESM5" ref-type="media">5</xref>: Figure S2.<fig id="Fig6"><label>Figure 6</label><caption><p>
<bold>Percentage of insoluble &#x003b1;-syn
phosphorylated at Ser129.</bold> Box-and-whisker plots
indicate the full range, interquartile range and median value
in each group. The percentage of insoluble &#x003b1;-syn
phosphorylated at Ser129 was significantly higher in PDD than
controls in all regions and in DLB in regions except the
midfrontal cortex. In addition, the percentage was
significantly higher in PDD than PDND in the midfrontal and
parahippocampal cortex, and in DLB than PDND in the cingulate
cortex. In the thalamus and parahippocampal cortex, the
percentage of insoluble &#x003b1;-syn phosphorylated at Ser129 was
significantly higher in PDND than controls. DLB, dementia
with Lewy bodies; PDD, Parkinson&#x02019;s disease with dementia;
PDND, Parkinson&#x02019;s disease without dementia; &#x003b1;-syn,
&#x003b1;-synuclein.</p></caption><graphic xlink:href="13195_2014_77_Fig6_HTML" id="MO6"/></fig><fig id="Fig7"><label>Figure 7</label><caption><p>
<bold>Percentage of soluble &#x003b1;-syn
phosphorylated at Ser129.</bold> The percentage of
soluble &#x003b1;-syn phosphorylated at Ser129 was significantly
higher in controls than in the PD groups in all regions
except midfrontal. The percentage of soluble &#x003b1;-syn
phosphorylated at Ser129 was also significantly higher in
controls than DLB in the cingulate. Conversely, the
percentage was significantly higher in DLB than PDND or PDD
in the parahippocampus and thalamus and significantly higher
in PDND than DLB in the midfrontal cortex. *<italic>P</italic> &#x0003c;0.05, **<italic>P</italic> &#x0003c;0.01, ***<italic>P</italic> &#x0003c;0.001. DLB, dementia with
Lewy bodies; PDD, Parkinson&#x02019;s disease with dementia; PDND,
Parkinson&#x02019;s disease without dementia; &#x003b1;-syn,
&#x003b1;-synuclein.</p></caption><graphic xlink:href="13195_2014_77_Fig7_HTML" id="MO7"/></fig></p></sec><sec id="Sec24"><title>MMSE score correlates negatively with insoluble pSer129 &#x003b1;-syn,
total insoluble &#x003b1;-syn and insoluble A&#x003b2;42</title><p>In all regions apart from the thalamus, the MMSE score
correlated negatively with the level of insoluble pSer129 &#x003b1;-syn
(Figure&#x000a0;<xref rid="Fig8" ref-type="fig">8</xref>) (midfrontal:
r&#x02009;=&#x02009;&#x02212;0.555, <italic>P</italic> = 0.017; cingulate:
r&#x02009;=&#x02009;&#x02212;0.816, <italic>P</italic> &#x0003c;0.0001;
parahippocampal cortex: r&#x02009;=&#x02009;&#x02212;0.752, <italic>P</italic>
= 0.0003). Furthermore, in the midfrontal region there was a significant
negative correlation between the MMSE score and both insoluble A&#x003b2;42
(r&#x02009;=&#x02009;&#x02212;0.591, P = 0.0098) and total insoluble &#x003b1;-syn (r&#x02009;=&#x02009;&#x02212;0.498, <italic>P</italic> = 0.036). No significant correlations were
observed between MMSE score and soluble A&#x003b2;42, A&#x003b2;40, total &#x003b1;-syn or
pSer129 &#x003b1;-syn. Time to dementia correlated negatively with soluble A&#x003b2;40
in this region (r&#x02009;=&#x02009;&#x02212;0.58, <italic>P</italic> = 0.048)
but did not show any other significant correlations (data not
shown).<fig id="Fig8"><label>Figure 8</label><caption><p>
<bold>Correlation between MMSE score and
insoluble A&#x003b2; or &#x003b1;-syn.</bold> The best-fit linear
regression (solid lines) and 95% confidence intervals
(interrupted lines) are superimposed. Only significant
<italic>P</italic>-values (and
associated correlation coefficients) are shown in the figure.
In all regions except the thalamus, the level of insoluble
pSer129 &#x003b1;-syn showed significant negative correlation with
the MMSE score. The score also showed a significant negative
correlation with midfrontal insoluble A&#x003b2;42 and total
insoluble &#x003b1;-syn. A&#x003b2;, amyloid-&#x003b2;; MMSE, mini-mental state
examination; pSer129 &#x003b1;-syn, alpha-synuclein phosphorylated at
serine 129; &#x003b1;-syn, &#x003b1;-synuclein.</p></caption><graphic xlink:href="13195_2014_77_Fig8_HTML" id="MO8"/></fig></p></sec><sec id="Sec25"><title>A&#x003b2; treatment induced phosphorylation at Ser129 in
&#x003b1;-syn-overexpressing SHSY-5Y cells</title><p>Exposure of cells to aggregated A&#x003b2;1-42 (10&#x000a0;&#x003bc;M)
significantly increased the percentage of &#x003b1;-syn in the insoluble fraction
that was phosphorylated at Ser129. Ser129 phosphorylation was also higher
after exposure to soluble 10&#x000a0;&#x003bc;M A&#x003b2;1-42 and aggregated (but not fresh)
10&#x000a0;&#x003bc;M A&#x003b2;1-40 but these increases did not reach statistical significance
(Figure&#x000a0;<xref rid="Fig9" ref-type="fig">9</xref>). There was a trend
towards a positive correlation (Spearman r = 0.49, <italic>P</italic> = 0.06) between the concentration of
aggregated A&#x003b2; and the percentage of &#x003b1;-syn phosphorylated at Ser129. In
the soluble fraction, the percentage of &#x003b1;-syn that was phosphorylated at
Ser129 was much lower and tended to decline after exposure to aggregated
A&#x003b2;1-42 and A&#x003b2;1-40 but not after exposure to fresh A&#x003b2; (Figure&#x000a0;<xref rid="Fig10" ref-type="fig">10</xref>).<fig id="Fig9"><label>Figure 9</label><caption><p>
<bold>Percentage of insoluble &#x003b1;-syn
phosphorylated at Ser129 after exposure of SH-SY5Y cells
to aggregated or soluble A&#x003b2;1-42 and A&#x003b2;1-40.</bold> The
percentage of insoluble &#x003b1;-syn that was phosphorylated at
Ser129 was significantly increased after 24&#x000a0;hours exposure of
the cells to 10&#x000a0;&#x003bc;M aggregated A&#x003b2;1-42 (<italic>P</italic> = 0.009). Ser129 phosphorylation was also
higher after exposure to soluble 10&#x000a0;&#x003bc;M A&#x003b2;1-42 and aggregated
10&#x000a0;&#x003bc;M A&#x003b2;1-40 but the increases did not reach significance.
A&#x003b2;, amyloid-&#x003b2;.</p></caption><graphic xlink:href="13195_2014_77_Fig9_HTML" id="MO9"/></fig><fig id="Fig10"><label>Figure 10</label><caption><p>
<bold>Percentage of soluble &#x003b1;-syn
phosphorylated at Ser129 after exposure of SH-SY5Y cells
to aggregated or soluble A&#x003b2;1-42 and A&#x003b2;1-40.</bold> The
percentage of soluble &#x003b1;-syn phosphorylated at Ser129 was much
lower than the figure for insoluble &#x003b1;-syn. The percentage
tended to fall after exposure to aggregated A&#x003b2;1-42 and
A&#x003b2;1-40, particularly at 10&#x000a0;&#x003bc;M, but not significantly so, and
did not change noticeably after exposure to soluble A&#x003b2;. The
bars show the mean and SE of measurements from five separate
experiments. A&#x003b2;, amyloid-&#x003b2;.</p></caption><graphic xlink:href="13195_2014_77_Fig10_HTML" id="MO10"/></fig></p></sec></sec><sec id="Sec26" sec-type="discussion"><title>Discussion</title><p>Although overlap between AD and DLB pathology occurs much more
often than would be expected by chance, the molecular basis is poorly
understood. Furthermore, the molecular changes underlying the development of
dementia in patients with PD are not fully understood. We found that most
parts of the cerebral cortex examined showed: (1) significant correlations
between phosphorylation of &#x003b1;-syn at Ser129 and the amount of soluble and
insoluble A&#x003b2;; (2) significant correlations between phosphorylation of &#x003b1;-syn
at Ser129 and Braak stage; (3) higher levels of soluble and insoluble A&#x003b2; in
PD and DLB than controls, and PDD and DLB than PDND; and (4) a higher
proportion of &#x003b1;-syn phosphorylated at Ser129 in PD and DLB than controls,
and PDD and DLB than PDND. Our study also showed that the proportion of
&#x003b1;-syn phosphorylated at Ser129 correlated with ante-mortem MMSE. Lastly, our
<italic>in vitro</italic> studies showed that exposure
of SH-SY5Y cells overexpressing wild-type &#x003b1;-syn to A&#x003b2;42 significantly
increased the proportion of &#x003b1;-syn that was phosphorylated at Ser129. These
biochemical studies extend previous findings of a synergistic relationship
between A&#x003b2; and &#x003b1;-syn and suggest that A&#x003b2;, particularly A&#x003b2;42, promotes the
phosphorylation of &#x003b1;-syn at Ser129.</p><p>Our biochemical studies support previous immunohistochemical
findings of a positive correlation between insoluble &#x003b1;-syn and A&#x003b2; in Lewy
body disease [<xref ref-type="bibr" rid="CR25">25</xref>,<xref ref-type="bibr" rid="CR26">26</xref>,<xref ref-type="bibr" rid="CR62">62</xref>-<xref ref-type="bibr" rid="CR64">64</xref>]. In
addition, our finding of a correlation with Braak stage, although more
restricted in terms of regions of the cortex, is in keeping with other
studies showing associations between &#x003b1;-syn and tangle pathology
[<xref ref-type="bibr" rid="CR7">7</xref>,<xref ref-type="bibr" rid="CR44">44</xref>] and suggest that there are multiple
interactions between Alzheimer-type and Lewy body-type pathology.
Deramecourt <italic>et al</italic>. [<xref ref-type="bibr" rid="CR7">7</xref>] reported that all patients with
sporadic DLB had abundant deposits of A&#x003b2;42. In addition, in families with
autosomal-dominant AD caused by amyloid precursor protein (APP) or
presenilin gene mutations, a high proportion of patients show LB pathology
at autopsy [<xref ref-type="bibr" rid="CR65">65</xref>,<xref ref-type="bibr" rid="CR66">66</xref>]. Furthermore, patients with mixed LB
and A&#x003b2; plaque pathology have a more aggressive disease course and more
pronounced cognitive dysfunction than do patients with pure AD [<xref ref-type="bibr" rid="CR19">19</xref>,<xref ref-type="bibr" rid="CR21">21</xref>-<xref ref-type="bibr" rid="CR23">23</xref>].
Transgenic mice expressing both human A&#x003b2; and &#x003b1;-syn also have more severe
deficits in learning and memory, and more intraneuronal &#x003b1;-syn inclusions
than do mice transgenic for &#x003b1;-syn alone [<xref ref-type="bibr" rid="CR28">28</xref>]. Other evidence comes from the observation by Kurata
<italic>et al</italic>. [<xref ref-type="bibr" rid="CR67">67</xref>], of enhanced accumulation of both A&#x003b2; and
phosphorylated &#x003b1;-syn in mice doubly transgenic for mutant APP and
presenilin-1 compared to that in mice transgenic for APP alone.</p><p>Obi <italic>et al</italic>. [<xref ref-type="bibr" rid="CR44">44</xref>] demonstrated an association between
A&#x003b2; and pSer129 &#x003b1;-syn detected immunohistochemically in the human temporal
neocortex human tissue, and we found a similar correlation in the
mid-frontal cortex. However, it was noteworthy that the correlation between
A&#x003b2; and pSer129 &#x003b1;-syn was less consistent in different brain regions when we
quantified these antigens immunohistochemically than by ELISA, and only a
weak, non-significant correlation was demonstrated between the
immunohistochemical and biochemical measurements. Several previous studies
have highlighted disparities between ELISA and immunohistochemistry
[<xref ref-type="bibr" rid="CR68">68</xref>-<xref ref-type="bibr" rid="CR70">70</xref>]. Some of these disparities are
thought to reflect the effects of formalin fixation and tissue processing on
the preservation of antigenic epitopes, and others may relate to a degree of
cross-linking of soluble and insoluble proteins, preventing their separate
analysis in the fixed, paraffin-embedded tissue. In addition, sandwich
ELISAs provide an objective measure of the actual concentration of the
analyte in a much larger, more representative volume of tissue than is
included in a paraffin section, and relies on a combination of two different
antibodies for specificity. Our biochemical methods also allowed us to
measure soluble protein. The significant negative correlations between
soluble pSer129 &#x003b1;-syn and A&#x003b2; are in keeping with an enhanced shift of
pSer129 &#x003b1;-syn into the insoluble fraction as a consequence of A&#x003b2;. The
present findings highlight the importance of combining biochemical
assessment with immunohistochemical methods when studying the quantitative
relationship between different proteins.</p><p>Direct molecular interaction between &#x003b1;-syn and A&#x003b2; was
demonstrated <italic>in vitro</italic>, by
multidimensional nuclear magnetic resonance (NMR) spectroscopy [<xref ref-type="bibr" rid="CR71">71</xref>]. A&#x003b2;42 interacted more strongly than
A&#x003b2;40 with &#x003b1;-syn, leading to major structural changes to &#x003b1;-syn, and its
oligomerization and precipitation within four hours. These findings may be
relevant to the observation by Bate <italic>et
al</italic>. [<xref ref-type="bibr" rid="CR72">72</xref>] who
observed that A&#x003b2;42 (but not A&#x003b2;40) enhanced &#x003b1;-syn-induced damage to synapses.
A&#x003b2;42 more strongly promoted the formation of higher molecular weight &#x003b1;-syn
polymers <italic>in vitro</italic> [<xref ref-type="bibr" rid="CR28">28</xref>]. In keeping with this, we found that
A&#x003b2;42 level generally correlated more strongly with pSer129 &#x003b1;-syn in human
brain tissue extracts than with A&#x003b2;40. We also showed that A&#x003b2;42 had a more
pronounced effect than A&#x003b2;40 on the phosphorylation of &#x003b1;-syn in SH-SY5Y
cells.</p><p><italic>In vitro</italic> studies have shown that &#x003b1;-syn
can be phosphorylated at Ser129 by CKI, CKII [<xref ref-type="bibr" rid="CR55">55</xref>], several G protein-coupled receptor kinases (GRKs 1,
2, 5, 6) [<xref ref-type="bibr" rid="CR73">73</xref>], leucine-rich
repeat kinase 2 (LRRK2) [<xref ref-type="bibr" rid="CR74">74</xref>]
and Polo-like kinases [<xref ref-type="bibr" rid="CR75">75</xref>,<xref ref-type="bibr" rid="CR76">76</xref>]. The
levels of CKI and CKII expression are elevated in both AD and DLB
[<xref ref-type="bibr" rid="CR76">76</xref>,<xref ref-type="bibr" rid="CR77">77</xref>], raising the possibility that these
enzymes may be involved in A&#x003b2;-induced phosphorylation of &#x003b1;-syn at Ser129,
similar to the A&#x003b2;-induced phosphorylation of tau [<xref ref-type="bibr" rid="CR78">78</xref>-<xref ref-type="bibr" rid="CR80">80</xref>].</p><p>More than 90% of &#x003b1;-syn in Lewy bodies and neurites is
phosphorylated at Ser129 [<xref ref-type="bibr" rid="CR34">34</xref>,<xref ref-type="bibr" rid="CR35">35</xref>]. The
importance of pSer129 &#x003b1;-syn was recognized in the Unified Lewy-type
Synucleinopathy Staging Scheme of Beach <italic>et
al</italic>. [<xref ref-type="bibr" rid="CR43">43</xref>], based
on the abundance and distribution of pSer129 &#x003b1;-syn. We have shown that
biochemical measurement of pSer129 &#x003b1;-syn by sandwich ELISA is an excellent
marker of Lewy body disease subtype. Previous studies have demonstrated the
utility of pSer129 &#x003b1;-syn measurement as a marker of disease stage
[<xref ref-type="bibr" rid="CR43">43</xref>,<xref ref-type="bibr" rid="CR44">44</xref>] and shown that the level is generally
higher in DLB and PDD than in PDND [<xref ref-type="bibr" rid="CR45">45</xref>]. The accumulation of pSer129 anticipates the
development of Lewy body pathology [<xref ref-type="bibr" rid="CR45">45</xref>,<xref ref-type="bibr" rid="CR81">81</xref>]. The
partitioning and enrichment of pSer129 &#x003b1;-syn in membrane and insoluble brain
fractions probably reflects changes in the conformation and solubility of
&#x003b1;-syn that promote its association with membrane structures [<xref ref-type="bibr" rid="CR82">82</xref>-<xref ref-type="bibr" rid="CR84">84</xref>]. Our data show that exposure of SH-SY5Y cells
overexpressing wild-type &#x003b1;-syn to A&#x003b2; results in a shift towards insoluble
pSer129 &#x003b1;-syn, with a trend towards loss of soluble pSer129 &#x003b1;-syn. In future
studies it would be of interest to investigate the distribution of &#x003b1;-syn and
pSer129 &#x003b1;-syn following A&#x003b2; exposure in this cell model and to determine the
enzymes responsible.</p><p>We have found a significant negative correlation between the
level of insoluble pSer129 &#x003b1;-syn and the MMSE score. This supports previous
work suggesting that Ser129 phosphorylation increases the neurotoxicity of
&#x003b1;-syn and is detrimental to cognitive function. Sato <italic>et al</italic>. [<xref ref-type="bibr" rid="CR85">85</xref>]
showed that pSer129 &#x003b1;-syn accelerated A53T &#x003b1;-syn-induced neurodegeneration;
this effect was abolished by inactivation of G-protein-coupled receptor
kinase 6 (GRK6) &#x02013; responsible for phosphorylation of &#x003b1;-syn at Ser129. In
contrast, enhancement of phosphatase activity in &#x003b1;-syn transgenic mice
caused a reduction of phosphorylated &#x003b1;-syn, increased dendritic arborization
of neurons in the cerebral cortex and reduced astroglial and microglial
activation [<xref ref-type="bibr" rid="CR39">39</xref>]. These
morphological effects were associated with improved motor performance.
Phosphorylation of &#x003b1;-syn at Ser129 was also shown to reduce &#x003b1;-syn-mediated
inhibition of tyrosine hydroxylase, an enzyme involved in catecholamine
synthesis; therefore, phosphorylation of &#x003b1;-syn may influence dopamine levels
[<xref ref-type="bibr" rid="CR86">86</xref>]. Although A&#x003b2;42, A&#x003b2;40
and total &#x003b1;-syn levels in several brain regions all correlated negatively
with MMSE score, those correlations were not as strong as that between MMSE
score and pSer129 &#x003b1;-syn. Our findings underscore the close association
between pSer129 &#x003b1;-syn accumulation and cognitive impairment, and do point to
a pathogenetic relationship between Ser129 phosphorylation of &#x003b1;-syn and
disease progression.</p></sec><sec id="Sec27" sec-type="conclusion"><title>Conclusions</title><p>Our findings in this study, the first to examine the
relationship between &#x003b1;-syn, pSer129, A&#x003b2;1-40 and A&#x003b2;1-42 levels in human
post-mortem brain tissue by sandwich ELISA, support the existence of a
pathogenic relationship between the accumulation of A&#x003b2;, particularly A&#x003b2;42,
and the phosphorylation of &#x003b1;-syn at Ser129, increasing the severity of Lewy
body disease and the likelihood of dementia. Further investigations are
required to determine the precise biochemical pathways responsible for this
interaction, the relative contributions of different processes (including
A&#x003b2;-associated Ser129 phosphorylation of &#x003b1;-syn and &#x003b1;-syn-associated
phosphorylation of tau) on the development of combined AD and Lewy body
pathology and the progression of neurodegeneration, and also the possible
influence of A&#x003b2; on other potential sites of &#x003b1;-syn phosphorylation.</p></sec></body><back><app-group><app id="App1"><sec id="Sec28"><title>Additional files</title><p><media position="anchor" xlink:href="13195_2014_77_MOESM1_ESM.jpeg" id="MOESM1"><label>Additional file 1: Figure S1.</label><caption><p>Dot blots demonstrating the specificity of the
phosphorylation-specific &#x003b1;-syn antibodies. Blots of
recombinant &#x003b1;-syn incubated with distilled water (&#x003b1;-syn)
casein kinase I (&#x003b1;-syn&#x02009;+&#x02009;CKI) or casein kinase II
(&#x003b1;-syn&#x02009;+&#x02009;CKII) and probed with pan-&#x003b1;-syn (column 1),
pSer129 &#x003b1;-syn (column 2) or pSer87 &#x003b1;-syn (column 3)
antibody. The pSer129 &#x003b1;-syn antibody labelled &#x003b1;-syn
following incubation with CKII, and to a lesser extent
CKI, but did not label recombinant &#x003b1;-syn that had not been
phosphorylated with CKI or CKII. Labeling with the
pSer87-specific &#x003b1;-syn antibody occurs only after
incubation of &#x003b1;-syn with CKI. These findings are as
predicted from the known patterns of phosphorylation of
&#x003b1;-syn with CKI and CKII.</p></caption></media><media position="anchor" xlink:href="13195_2014_77_MOESM2_ESM.docx" id="MOESM2"><label>Additional file 2: Table S3.</label><caption><p>Intra-assay coefficient of variation (CV) from
insoluble (shaded) and soluble A&#x003b2;42, A&#x003b2;40, total &#x003b1;-syn and
pSer129 &#x003b1;-syn ELISAs.</p></caption></media><media position="anchor" xlink:href="13195_2014_77_MOESM3_ESM.docx" id="MOESM3"><label>Additional file 3: Table S1.</label><caption><p>Correlation between levels of A&#x003b2; and &#x003b1;-syn in the
midfrontal, cingulate and parahippocampal cortex and the
thalamus.</p></caption></media><media position="anchor" xlink:href="13195_2014_77_MOESM4_ESM.docx" id="MOESM4"><label>Additional file 4: Table S2.</label><caption><p>Correlation between levels of A&#x003b2; and &#x003b1;-syn in the
midfrontal, cingulate and parahippocampal cortex and the
thalamus from immunohistochemistry field fraction
analyses.</p></caption></media><media position="anchor" xlink:href="13195_2014_77_MOESM5_ESM.jpeg" id="MOESM5"><label>Additional file 5: Figure S2.</label><caption><p>pSer129 &#x003b1;-syn levels in controls*, PDND, PDD and
DLB. Box-and-whisker plots indicate the full range,
interquartile range and median value in each group.
Insoluble pSer129 &#x003b1;-syn levels were significantly higher
in PD groups compared with controls in the midfrontal
region. PDD patients also showed significantly higher
levels of insoluble pSer129 &#x003b1;-syn compared with PDND and
DLB in the same region. All disease groups showed
significantly higher levels of insoluble pSer129 &#x003b1;-syn
levels compared with controls in the cingulate region. No
significant difference in insoluble pSer129 &#x003b1;-syn levels
were observed in the parahippocampal cortex and thalamus.
Soluble pSer129 &#x003b1;-syn levels were significantly higher in
PD groups compared with controls and DLB in the midfrontal
region. In contrast, soluble pSer129 levels were
significantly higher in controls and DLB compared with PD
groups in the parahippocampal region. *Control n numbers
varied in the following assays due to limited tissue
availability (soluble fraction: total &#x003b1;-syn: midfrontal n
= 13, cingulate n = 10, parahippocampal n = 16, thalamus n
= 16; pSer129 &#x003b1;-syn: midfrontal n = 5, cingulate n = 12,
parahippocampal n = 14; A&#x003b2;42: midfrontal n = 13, cingulate
n =16; A&#x003b2;40: midfrontal n = 9, cingulate n = 14,
parahippocampal n = 16).</p></caption></media></p></sec></app></app-group><glossary><title>Abbreviations</title><def-list><def-list><def-item><term>AD</term><def><p>Alzheimer&#x02019;s disease</p></def></def-item><def-item><term>ANOVA</term><def><p>analysis of variance</p></def></def-item><def-item><term>APP</term><def><p>amyloid precursor protein</p></def></def-item><def-item><term>A&#x003b2;</term><def><p>amyloid-beta</p></def></def-item><def-item><term>BSA</term><def><p>bovine serum albumin</p></def></def-item><def-item><term>CKI</term><def><p>casein kinase I</p></def></def-item><def-item><term>CKII</term><def><p>casein kinase II</p></def></def-item><def-item><term>CMV</term><def><p>cytomegalovirus</p></def></def-item><def-item><term>DLB</term><def><p>dementia with Lewy bodies</p></def></def-item><def-item><term>EDTA</term><def><p>ethylenediaminetetraacetic acid</p></def></def-item><def-item><term>ELISA</term><def><p>enzyme-linked immunosorbent assay</p></def></def-item><def-item><term>GuHCl</term><def><p>guanidinium chloride</p></def></def-item><def-item><term>HRP</term><def><p>horseradish peroxidase</p></def></def-item><def-item><term>MMSE</term><def><p>mini-mental state examination</p></def></def-item><def-item><term>PBS</term><def><p>phosphate-buffered saline</p></def></def-item><def-item><term>PD</term><def><p>Parkinson&#x02019;s disease</p></def></def-item><def-item><term>PDD</term><def><p>Parkinson&#x02019;s disease with dementia</p></def></def-item><def-item><term>PDND</term><def><p>Parkinson&#x02019;s disease without dementia</p></def></def-item><def-item><term>pSer129 &#x003b1;-syn</term><def><p>alpha-synuclein phosphorylated at serine 129</p></def></def-item><def-item><term>QSBB</term><def><p>Queen Square Brain Bank</p></def></def-item><def-item><term>RT</term><def><p>room temperature</p></def></def-item><def-item><term>Ser129</term><def><p>serine 129</p></def></def-item><def-item><term>SWDBB</term><def><p>South West Dementia Brain Bank</p></def></def-item><def-item><term>TBS</term><def><p>Tris-buffered saline</p></def></def-item><def-item><term>TBST</term><def><p>Tris-buffered saline with Tween 20</p></def></def-item><def-item><term>TRIS</term><def><p>tris(hydroxymethyl)aminomethane</p></def></def-item><def-item><term>&#x003b1;-syn</term><def><p>alpha-synuclein</p></def></def-item></def-list></def-list></glossary><fn-group><fn><p><bold>Competing interests</bold></p><p>The authors declare that they have no competing
interests.</p></fn><fn><p><bold>Authors&#x02019; contributions</bold></p><p>SL, JSM, JH and TR designed the study. RdS developed and
characterized the SH-SY5Y cells expressing human wild-type &#x003b1;-syn, MS and JSM
performed all of the other laboratory studies on the SH-SY5Y cells and on
brain tissue; TL, JH and TR performed the neuropathological characterization
of most the PDND and PDD cases; HL reviewed the clinical records and
retrieved the MMSE scores; MS, JSM and SL analyzed the data and drafted the
manuscript. All of the authors read and approved the final
manuscript.</p></fn></fn-group><ack><title>Acknowledgements</title><p>This research was supported by grants from Alzheimer&#x02019;s Research UK
and BRACE (Bristol Research into Ageing and Care of the Elderly). The South
West Dementia Brain Bank was also supported by ABBUK (Alzheimer&#x02019;s Brain Bank
UK, supporting Brains for Dementia Research). The Queen Square Brain Bank is
supported by the Reta Lila Weston Institute of Neurological Studies, UCL
Institute of Neurology and the PSP Association. Part of this work was
undertaken at UCLH/UCL who received a proportion of funding from the
Department of Health&#x02019;s NIHR Biomedical Research Centres funding scheme and,
in part, funded/supported by the National Institute for Health Research
(NIHR) Biomedical Research Unit in Dementia based at University College
London Hospitals (UCLH), University College London (UCL). RdeS was funded by
the Reta Lila Weston Trust for Medical Research.</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mayeux</surname><given-names>R</given-names></name><name><surname>Stern</surname><given-names>Y</given-names></name></person-group><article-title>Epidemiology of Alzheimer
disease</article-title><source>Cold Spring Harb Perspect Med</source><year>2012</year><volume>2</volume><fpage>a006239</fpage><pub-id pub-id-type="doi">10.1101/cshperspect.a006239</pub-id><pub-id pub-id-type="pmid">22908189</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nowrangi</surname><given-names>MA</given-names></name><name><surname>Rao</surname><given-names>V</given-names></name><name><surname>Lyketsos</surname><given-names>CG</given-names></name></person-group><article-title>Epidemiology, assessment, and treatment of
dementia</article-title><source>Psychiatr Clin North Am</source><year>2011</year><volume>34</volume><fpage>275</fpage><pub-id pub-id-type="doi">10.1016/j.psc.2011.02.004</pub-id><pub-id pub-id-type="pmid">21536159</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forno</surname><given-names>LS</given-names></name></person-group><article-title>Neuropathology of Parkinson&#x02019;s
disease</article-title><source>J Neuropathol Exp Neurol</source><year>1996</year><volume>55</volume><fpage>259</fpage><lpage>272</lpage><pub-id pub-id-type="doi">10.1097/00005072-199603000-00001</pub-id><pub-id pub-id-type="pmid">8786384</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pollanen</surname><given-names>MS</given-names></name><name><surname>Dickson</surname><given-names>DW</given-names></name><name><surname>Bergeron</surname><given-names>C</given-names></name></person-group><article-title>Pathology and biology of the Lewy
body</article-title><source>J Neuropathol Exp Neurol</source><year>1993</year><volume>52</volume><fpage>183</fpage><lpage>191</lpage><pub-id pub-id-type="doi">10.1097/00005072-199305000-00001</pub-id><pub-id pub-id-type="pmid">7684074</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spillantini</surname><given-names>MG</given-names></name><name><surname>Schmidt</surname><given-names>ML</given-names></name><name><surname>Lee</surname><given-names>VM</given-names></name><name><surname>Trojanowski</surname><given-names>JQ</given-names></name><name><surname>Jakes</surname><given-names>R</given-names></name><name><surname>Goedert</surname><given-names>M</given-names></name></person-group><article-title>&#x003b1;-Synuclein in Lewy bodies</article-title><source>Nature</source><year>1997</year><volume>388</volume><fpage>839</fpage><lpage>840</lpage><pub-id pub-id-type="doi">10.1038/42166</pub-id><pub-id pub-id-type="pmid">9278044</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bergeron</surname><given-names>C</given-names></name><name><surname>Pollanen</surname><given-names>M</given-names></name></person-group><article-title>Lewy bodies in Alzheimer disease&#x02013;one or two
diseases?</article-title><source>Alzheimer Dis Assoc Disord</source><year>1989</year><volume>3</volume><fpage>197</fpage><pub-id pub-id-type="doi">10.1097/00002093-198900000-00002</pub-id><pub-id pub-id-type="pmid">2557056</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deramecourt</surname><given-names>V</given-names></name><name><surname>Bombois</surname><given-names>S</given-names></name><name><surname>Maurage</surname><given-names>CA</given-names></name><name><surname>Ghestem</surname><given-names>A</given-names></name><name><surname>Drobecq</surname><given-names>H</given-names></name><name><surname>Vanmechelen</surname><given-names>E</given-names></name><name><surname>Lebert</surname><given-names>F</given-names></name><name><surname>Pasquier</surname><given-names>F</given-names></name><name><surname>Delacourte</surname><given-names>A</given-names></name></person-group><article-title>Biochemical staging of synucleinopathy and
amyloid deposition in dementia with Lewy bodies</article-title><source>J Neuropathol Exp Neurol</source><year>2006</year><volume>65</volume><fpage>278</fpage><lpage>288</lpage><pub-id pub-id-type="doi">10.1097/01.jnen.0000205145.54457.ea</pub-id><pub-id pub-id-type="pmid">16651889</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dickson</surname><given-names>D</given-names></name><name><surname>Crystal</surname><given-names>H</given-names></name><name><surname>Mattiace</surname><given-names>L</given-names></name><name><surname>Kress</surname><given-names>Y</given-names></name><name><surname>Schwagerl</surname><given-names>A</given-names></name><name><surname>Ksiezak-Reding</surname><given-names>H</given-names></name><name><surname>Davies</surname><given-names>P</given-names></name><name><surname>Yen</surname><given-names>SH</given-names></name></person-group><article-title>Diffuse Lewy body disease: light and electron
microscopic immunocytochemistry of senile plaques</article-title><source>Acta Neuropathol</source><year>1989</year><volume>78</volume><fpage>572</fpage><lpage>584</lpage><pub-id pub-id-type="doi">10.1007/BF00691284</pub-id><pub-id pub-id-type="pmid">2683563</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gibb</surname><given-names>W</given-names></name><name><surname>Mountjoy</surname><given-names>C</given-names></name><name><surname>Mann</surname><given-names>D</given-names></name><name><surname>Lees</surname><given-names>A</given-names></name></person-group><article-title>A pathological study of the association
between Lewy body disease and Alzheimer&#x02019;s disease</article-title><source>J Neurol Neurosurg Psychiatry</source><year>1989</year><volume>52</volume><fpage>701</fpage><lpage>708</lpage><pub-id pub-id-type="doi">10.1136/jnnp.52.6.701</pub-id><pub-id pub-id-type="pmid">2545826</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamilton</surname><given-names>RL</given-names></name></person-group><article-title>Lewy bodies in Alzheimer&#x02019;s disease: a
neuropathological review of 145 cases using &#x003b1;-synuclein
immunohistochemistry</article-title><source>Brain Pathol</source><year>2000</year><volume>10</volume><fpage>378</fpage><lpage>384</lpage><pub-id pub-id-type="doi">10.1111/j.1750-3639.2000.tb00269.x</pub-id><pub-id pub-id-type="pmid">10885656</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Irwin</surname><given-names>DJ</given-names></name><name><surname>Lee</surname><given-names>VM</given-names></name><name><surname>Trojanowski</surname><given-names>JQ</given-names></name></person-group><article-title>Parkinson&#x02019;s disease dementia: convergence of
&#x003b1;-synuclein, tau and amyloid-&#x003b2; pathologies</article-title><source>Nat Rev Neurosci</source><year>2013</year><volume>14</volume><fpage>626</fpage><lpage>636</lpage><pub-id pub-id-type="doi">10.1038/nrn3549</pub-id><pub-id pub-id-type="pmid">23900411</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Irwin</surname><given-names>DJ</given-names></name><name><surname>White</surname><given-names>MT</given-names></name><name><surname>Toledo</surname><given-names>JB</given-names></name><name><surname>Xie</surname><given-names>SX</given-names></name><name><surname>Robinson</surname><given-names>JL</given-names></name><name><surname>Van Deerlin</surname><given-names>V</given-names></name><name><surname>Lee</surname><given-names>VM</given-names></name><name><surname>Leverenz</surname><given-names>JB</given-names></name><name><surname>Montine</surname><given-names>TJ</given-names></name><name><surname>Duda</surname><given-names>JE</given-names></name><name><surname>Hurtig</surname><given-names>HI</given-names></name><name><surname>Trojanowski</surname><given-names>JQ</given-names></name></person-group><article-title>Neuropathologic substrates of Parkinson
disease dementia</article-title><source>Ann Neurol</source><year>2012</year><volume>72</volume><fpage>587</fpage><lpage>598</lpage><pub-id pub-id-type="doi">10.1002/ana.23659</pub-id><pub-id pub-id-type="pmid">23037886</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mikolaenko</surname><given-names>I</given-names></name><name><surname>Pletnikova</surname><given-names>O</given-names></name><name><surname>Kawas</surname><given-names>CH</given-names></name><name><surname>O'Brien</surname><given-names>R</given-names></name><name><surname>Resnick</surname><given-names>SM</given-names></name><name><surname>Crain</surname><given-names>B</given-names></name><name><surname>Troncoso</surname><given-names>JC</given-names></name></person-group><article-title>Alpha-synuclein lesions in normal aging,
Parkinson disease, and Alzheimer disease: evidence from the Baltimore
Longitudinal Study of Aging (BLSA)</article-title><source>J Neuropathol Exp Neurol</source><year>2005</year><volume>64</volume><fpage>156</fpage><lpage>162</lpage><pub-id pub-id-type="pmid">15751230</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parkkinen</surname><given-names>L</given-names></name><name><surname>Pirttil&#x000e4;</surname><given-names>T</given-names></name><name><surname>Alafuzoff</surname><given-names>I</given-names></name></person-group><article-title>Applicability of current
staging/categorization of &#x003b1;-synuclein pathology and their clinical
relevance</article-title><source>Acta Neuropathol</source><year>2008</year><volume>115</volume><fpage>399</fpage><lpage>407</lpage><pub-id pub-id-type="doi">10.1007/s00401-008-0346-6</pub-id><pub-id pub-id-type="pmid">18297293</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saito</surname><given-names>Y</given-names></name><name><surname>Kawashima</surname><given-names>A</given-names></name><name><surname>Ruberu</surname><given-names>NN</given-names></name><name><surname>Fujiwara</surname><given-names>H</given-names></name><name><surname>Koyama</surname><given-names>S</given-names></name><name><surname>Sawabe</surname><given-names>M</given-names></name><name><surname>Arai</surname><given-names>T</given-names></name><name><surname>Nagura</surname><given-names>H</given-names></name><name><surname>Yamanouchi</surname><given-names>H</given-names></name><name><surname>Hasegawa</surname><given-names>M</given-names></name><name><surname>Iwatsubo</surname><given-names>T</given-names></name><name><surname>Murayama</surname><given-names>S</given-names></name></person-group><article-title>Accumulation of phosphorylated &#x003b1;-synuclein in
aging human brain</article-title><source>J Neuropathol Exp Neurol</source><year>2003</year><volume>62</volume><fpage>644</fpage><lpage>654</lpage><pub-id pub-id-type="pmid">12834109</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uchikado</surname><given-names>H</given-names></name><name><surname>Lin</surname><given-names>WL</given-names></name><name><surname>DeLucia</surname><given-names>MW</given-names></name><name><surname>Dickson</surname><given-names>DW</given-names></name></person-group><article-title>Alzheimer disease with amygdala Lewy bodies:
a distinct form of &#x003b1;-synucleinopathy</article-title><source>J Neuropathol Exp Neurol</source><year>2006</year><volume>65</volume><fpage>685</fpage><lpage>697</lpage><pub-id pub-id-type="doi">10.1097/01.jnen.0000225908.90052.07</pub-id><pub-id pub-id-type="pmid">16825955</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galpern</surname><given-names>WR</given-names></name><name><surname>Lang</surname><given-names>AE</given-names></name></person-group><article-title>Interface between tauopathies and
synucleinopathies: a tale of two proteins</article-title><source>Ann Neurol</source><year>2006</year><volume>59</volume><fpage>449</fpage><lpage>458</lpage><pub-id pub-id-type="doi">10.1002/ana.20819</pub-id><pub-id pub-id-type="pmid">16489609</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Halliday</surname><given-names>G</given-names></name><name><surname>Hely</surname><given-names>M</given-names></name><name><surname>Reid</surname><given-names>W</given-names></name><name><surname>Morris</surname><given-names>J</given-names></name></person-group><article-title>The progression of pathology in
longitudinally followed patients with Parkinson&#x02019;s
disease</article-title><source>Acta Neuropathol</source><year>2008</year><volume>115</volume><fpage>409</fpage><lpage>415</lpage><pub-id pub-id-type="doi">10.1007/s00401-008-0344-8</pub-id><pub-id pub-id-type="pmid">18231798</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hansen</surname><given-names>L</given-names></name><name><surname>Salmon</surname><given-names>D</given-names></name><name><surname>Galasko</surname><given-names>D</given-names></name><name><surname>Masliah</surname><given-names>E</given-names></name><name><surname>Katzman</surname><given-names>R</given-names></name><name><surname>Deteresa</surname><given-names>R</given-names></name><name><surname>Thal</surname><given-names>L</given-names></name><name><surname>Pay</surname><given-names>MM</given-names></name><name><surname>Hofstetter</surname><given-names>R</given-names></name><name><surname>Klauber</surname><given-names>M</given-names></name><name><surname>Rice</surname><given-names>V</given-names></name><name><surname>Butters</surname><given-names>N</given-names></name><name><surname>Alford</surname><given-names>M</given-names></name></person-group><article-title>The Lewy body variant of Alzheimer&#x02019;s disease
- a clinical and pathological entity</article-title><source>Neurology</source><year>1990</year><volume>40</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1212/WNL.40.1.1</pub-id><pub-id pub-id-type="pmid">2153271</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kosaka</surname><given-names>K</given-names></name><name><surname>Yoshimura</surname><given-names>M</given-names></name><name><surname>Ikeda</surname><given-names>K</given-names></name><name><surname>Budka</surname><given-names>H</given-names></name></person-group><article-title>Diffuse type of Lewy body disease -
progressive dementia with abundant cortical Lewy bodies and senile
changes of varying degree - a new disease</article-title><source>Clin Neuropathol</source><year>1984</year><volume>3</volume><fpage>185</fpage><lpage>192</lpage><pub-id pub-id-type="pmid">6094067</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kraybill</surname><given-names>ML</given-names></name><name><surname>Larson</surname><given-names>EB</given-names></name><name><surname>Tsuang</surname><given-names>DW</given-names></name><name><surname>Teri</surname><given-names>L</given-names></name><name><surname>McCormick</surname><given-names>WC</given-names></name><name><surname>Bowen</surname><given-names>JD</given-names></name><name><surname>Kukull</surname><given-names>WA</given-names></name><name><surname>Leverenz</surname><given-names>JB</given-names></name><name><surname>Cherrier</surname><given-names>MM</given-names></name></person-group><article-title>Cognitive differences in dementia patients
with autopsy-verified AD, Lewy body pathology, or both</article-title><source>Neurology</source><year>2005</year><volume>64</volume><fpage>2069</fpage><lpage>2073</lpage><pub-id pub-id-type="doi">10.1212/01.WNL.0000165987.89198.65</pub-id><pub-id pub-id-type="pmid">15985574</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langlais</surname><given-names>PJ</given-names></name><name><surname>Thal</surname><given-names>L</given-names></name><name><surname>Hansen</surname><given-names>L</given-names></name><name><surname>Galasko</surname><given-names>D</given-names></name><name><surname>Alford</surname><given-names>M</given-names></name><name><surname>Masliah</surname><given-names>E</given-names></name></person-group><article-title>Neurotransmitters in basal ganglia and cortex
of Alzheimer&#x02019;s disease with and without Lewy bodies</article-title><source>Neurology</source><year>1993</year><volume>43</volume><fpage>1927</fpage><lpage>1934</lpage><pub-id pub-id-type="doi">10.1212/WNL.43.10.1927</pub-id><pub-id pub-id-type="pmid">8105420</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olichney</surname><given-names>JM</given-names></name><name><surname>Galasko</surname><given-names>D</given-names></name><name><surname>Salmon</surname><given-names>DP</given-names></name><name><surname>Hofstetter</surname><given-names>CR</given-names></name><name><surname>Katzman</surname><given-names>R</given-names></name><name><surname>Thal</surname><given-names>LJ</given-names></name></person-group><article-title>Cognitive decline is faster in Lewy body
variant than in Alzheimer&#x02019;s disease</article-title><source>Neurology</source><year>1998</year><volume>51</volume><fpage>351</fpage><lpage>357</lpage><pub-id pub-id-type="doi">10.1212/WNL.51.2.351</pub-id><pub-id pub-id-type="pmid">9710002</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trojanowski</surname><given-names>JQ</given-names></name></person-group><article-title>Emerging Alzheimer&#x02019;s disease therapies:
focusing on the future</article-title><source>Neurobiol Aging</source><year>2002</year><volume>23</volume><fpage>985</fpage><lpage>990</lpage><pub-id pub-id-type="doi">10.1016/S0197-4580(02)00123-9</pub-id><pub-id pub-id-type="pmid">12470793</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lashley</surname><given-names>T</given-names></name><name><surname>Holton</surname><given-names>JL</given-names></name><name><surname>Gray</surname><given-names>E</given-names></name><name><surname>Kirkham</surname><given-names>K</given-names></name><name><surname>O'Sullivan</surname><given-names>SS</given-names></name><name><surname>Hilbig</surname><given-names>A</given-names></name><name><surname>Wood</surname><given-names>NW</given-names></name><name><surname>Lees</surname><given-names>AJ</given-names></name><name><surname>Revesz</surname><given-names>T</given-names></name></person-group><article-title>Cortical &#x003b1;-synuclein load is associated with
amyloid-&#x003b2; plaque burden in a subset of Parkinson&#x02019;s disease
patients</article-title><source>Acta Neuropathol</source><year>2008</year><volume>115</volume><fpage>417</fpage><lpage>425</lpage><pub-id pub-id-type="doi">10.1007/s00401-007-0336-0</pub-id><pub-id pub-id-type="pmid">18185940</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pletnikova</surname><given-names>O</given-names></name><name><surname>West</surname><given-names>N</given-names></name><name><surname>Lee</surname><given-names>MK</given-names></name><name><surname>Rudow</surname><given-names>GL</given-names></name><name><surname>Skolasky</surname><given-names>RL</given-names></name><name><surname>Dawson</surname><given-names>TM</given-names></name><name><surname>Marsh</surname><given-names>L</given-names></name><name><surname>Troncoso</surname><given-names>JC</given-names></name></person-group><article-title>A&#x003b2; deposition is associated with enhanced
cortical &#x003b1;-synuclein lesions in Lewy body diseases</article-title><source>Neurobiol Aging</source><year>2005</year><volume>26</volume><fpage>1183</fpage><lpage>1192</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2004.10.006</pub-id><pub-id pub-id-type="pmid">15917102</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wirths</surname><given-names>O</given-names></name><name><surname>Weickert</surname><given-names>S</given-names></name><name><surname>Majtenyi</surname><given-names>K</given-names></name><name><surname>Havas</surname><given-names>L</given-names></name><name><surname>Kahle</surname><given-names>PJ</given-names></name><name><surname>Okochi</surname><given-names>M</given-names></name><name><surname>Haass</surname><given-names>C</given-names></name><name><surname>Multhaup</surname><given-names>G</given-names></name><name><surname>Beyreuther</surname><given-names>K</given-names></name><name><surname>Bayer</surname><given-names>TA</given-names></name></person-group><article-title>Lewy body variant of Alzheimer&#x02019;s disease:
&#x003b1;-synuclein in dystrophic neurites of A&#x003b2; plaques</article-title><source>Neuroreport</source><year>2000</year><volume>11</volume><fpage>3737</fpage><lpage>3741</lpage><pub-id pub-id-type="doi">10.1097/00001756-200011270-00029</pub-id><pub-id pub-id-type="pmid">11117482</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masliah</surname><given-names>E</given-names></name><name><surname>Rockenstein</surname><given-names>E</given-names></name><name><surname>Veinbergs</surname><given-names>I</given-names></name><name><surname>Sagara</surname><given-names>Y</given-names></name><name><surname>Mallory</surname><given-names>M</given-names></name><name><surname>Hashimoto</surname><given-names>M</given-names></name><name><surname>Mucke</surname><given-names>L</given-names></name></person-group><article-title>&#x003b2;-Amyloid peptides enhance &#x003b1;-synuclein
accumulation and neuronal deficits in a transgenic mouse model linking
Alzheimer&#x02019;s disease and Parkinson&#x02019;s disease</article-title><source>Proc Natl Acad Sci U S A</source><year>2001</year><volume>98</volume><fpage>12245</fpage><lpage>12250</lpage><pub-id pub-id-type="doi">10.1073/pnas.211412398</pub-id><pub-id pub-id-type="pmid">11572944</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moskvina</surname><given-names>V</given-names></name><name><surname>Harold</surname><given-names>D</given-names></name><name><surname>Russo</surname><given-names>G</given-names></name><name><surname>Vedernikov</surname><given-names>A</given-names></name><name><surname>Sharma</surname><given-names>M</given-names></name><name><surname>Saad</surname><given-names>M</given-names></name><name><surname>Holmans</surname><given-names>P</given-names></name><name><surname>Bras</surname><given-names>JM</given-names></name><name><surname>Bettella</surname><given-names>F</given-names></name><name><surname>Keller</surname><given-names>MF</given-names></name><name><surname>Nicolaou</surname><given-names>N</given-names></name><name><surname>Sim&#x000f3;n-S&#x000e1;nchez</surname><given-names>J</given-names></name><name><surname>Gibbs</surname><given-names>JR</given-names></name><name><surname>Schulte</surname><given-names>C</given-names></name><name><surname>Durr</surname><given-names>A</given-names></name><name><surname>Guerreiro</surname><given-names>R</given-names></name><name><surname>Hernandez</surname><given-names>D</given-names></name><name><surname>Brice</surname><given-names>A</given-names></name><name><surname>Stef&#x000e1;nsson</surname><given-names>H</given-names></name><name><surname>Majamaa</surname><given-names>K</given-names></name><name><surname>Gasser</surname><given-names>T</given-names></name><name><surname>Heutink</surname><given-names>P</given-names></name><name><surname>Wood</surname><given-names>N</given-names></name><name><surname>Martinez</surname><given-names>M</given-names></name><name><surname>Singleton</surname><given-names>AB</given-names></name><name><surname>Nalls</surname><given-names>MA</given-names></name><name><surname>Hardy</surname><given-names>J</given-names></name><name><surname>Owen</surname><given-names>MJ</given-names></name><name><surname>O'Donovan</surname><given-names>MC</given-names></name><name><surname>Williams</surname><given-names>J</given-names></name><etal/></person-group><article-title>Analysis of genome-wide association studies
of Alzheimer disease and of Parkinson disease to determine if these 2
diseases share a common genetic risk</article-title><source>JAMA Neurol</source><year>2013</year><volume>70</volume><fpage>1268</fpage><lpage>1276</lpage><pub-id pub-id-type="pmid">23921447</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jensen</surname><given-names>PH</given-names></name><name><surname>Hager</surname><given-names>H</given-names></name><name><surname>Nielsen</surname><given-names>MS</given-names></name><name><surname>H&#x000f8;jrup</surname><given-names>P</given-names></name><name><surname>Gliemann</surname><given-names>J</given-names></name><name><surname>Jakes</surname><given-names>R</given-names></name></person-group><article-title>&#x003b1;-Synuclein binds to tau and stimulates the
protein kinase A-catalyzed tau phosphorylation of serine residues 262
and 356</article-title><source>J Biol Chem</source><year>1999</year><volume>274</volume><fpage>25481</fpage><lpage>25489</lpage><pub-id pub-id-type="doi">10.1074/jbc.274.36.25481</pub-id><pub-id pub-id-type="pmid">10464279</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duka</surname><given-names>T</given-names></name><name><surname>Duka</surname><given-names>V</given-names></name><name><surname>Joyce</surname><given-names>JN</given-names></name><name><surname>Sidhu</surname><given-names>A</given-names></name></person-group><article-title>&#x003b1;-Synuclein contributes to GSK-3&#x003b2;-catalyzed
tau phosphorylation in Parkinson&#x02019;s disease models</article-title><source>FASEB J</source><year>2009</year><volume>23</volume><fpage>2820</fpage><lpage>2830</lpage><pub-id pub-id-type="doi">10.1096/fj.08-120410</pub-id><pub-id pub-id-type="pmid">19369384</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawakami</surname><given-names>F</given-names></name><name><surname>Suzuki</surname><given-names>M</given-names></name><name><surname>Shimada</surname><given-names>N</given-names></name><name><surname>Kagiya</surname><given-names>G</given-names></name><name><surname>Ohta</surname><given-names>E</given-names></name><name><surname>Tamura</surname><given-names>K</given-names></name><name><surname>Maruyama</surname><given-names>H</given-names></name><name><surname>Ichikawa</surname><given-names>T</given-names></name></person-group><article-title>Stimulatory effect of &#x003b1;-synuclein on the
tau-phosphorylation by GSK-3&#x003b2;</article-title><source>FEBS J</source><year>2011</year><volume>278</volume><fpage>4895</fpage><lpage>4904</lpage><pub-id pub-id-type="doi">10.1111/j.1742-4658.2011.08389.x</pub-id><pub-id pub-id-type="pmid">21985244</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edison</surname><given-names>P</given-names></name><name><surname>Rowe</surname><given-names>CC</given-names></name><name><surname>Rinne</surname><given-names>JO</given-names></name><name><surname>Ng</surname><given-names>S</given-names></name><name><surname>Ahmed</surname><given-names>I</given-names></name><name><surname>Kemppainen</surname><given-names>N</given-names></name><name><surname>Villemagne</surname><given-names>VL</given-names></name><name><surname>O&#x02019;Keefe</surname><given-names>G</given-names></name><name><surname>N&#x000e5;gren</surname><given-names>K</given-names></name><name><surname>Chaudhury</surname><given-names>K</given-names></name><name><surname>Masters</surname><given-names>CL</given-names></name><name><surname>Brooks</surname><given-names>DJ</given-names></name></person-group><article-title>Amyloid load in Parkinson&#x02019;s disease dementia
and Lewy body dementia measured with [11C] PIB positron emission
tomography</article-title><source>J Neurol Neurosurg Psychiatry</source><year>2008</year><volume>79</volume><fpage>1331</fpage><lpage>1338</lpage><pub-id pub-id-type="doi">10.1136/jnnp.2007.127878</pub-id><pub-id pub-id-type="pmid">18653550</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>JP</given-names></name><name><surname>Walker</surname><given-names>DE</given-names></name><name><surname>Goldstein</surname><given-names>JM</given-names></name><name><surname>de Laat</surname><given-names>R</given-names></name><name><surname>Banducci</surname><given-names>K</given-names></name><name><surname>Caccavello</surname><given-names>RJ</given-names></name><name><surname>Barbour</surname><given-names>R</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Kling</surname><given-names>K</given-names></name><name><surname>Lee</surname><given-names>M</given-names></name><name><surname>Diep</surname><given-names>L</given-names></name><name><surname>Keim</surname><given-names>PS</given-names></name><name><surname>Shen</surname><given-names>X</given-names></name><name><surname>Chataway</surname><given-names>T</given-names></name><name><surname>Schlossmacher</surname><given-names>MG</given-names></name><name><surname>Seubert</surname><given-names>P</given-names></name><name><surname>Schenk</surname><given-names>D</given-names></name><name><surname>Sinha</surname><given-names>S</given-names></name><name><surname>Gai</surname><given-names>WP</given-names></name><name><surname>Chilcote</surname><given-names>TJ</given-names></name></person-group><article-title>Phosphorylation of Ser-129 is the dominant
pathological modification of &#x003b1;-synuclein in familial and sporadic Lewy
body disease</article-title><source>J Biol Chem</source><year>2006</year><volume>281</volume><fpage>29739</fpage><lpage>29752</lpage><pub-id pub-id-type="doi">10.1074/jbc.M600933200</pub-id><pub-id pub-id-type="pmid">16847063</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fujiwara</surname><given-names>H</given-names></name><name><surname>Hasegawa</surname><given-names>M</given-names></name><name><surname>Dohmae</surname><given-names>N</given-names></name><name><surname>Kawashima</surname><given-names>A</given-names></name><name><surname>Masliah</surname><given-names>E</given-names></name><name><surname>Goldberg</surname><given-names>MS</given-names></name><name><surname>Shen</surname><given-names>J</given-names></name><name><surname>Takio</surname><given-names>K</given-names></name><name><surname>Iwatsubo</surname><given-names>T</given-names></name></person-group><article-title>&#x003b1;-Synuclein is phosphorylated in
synucleinopathy lesions</article-title><source>Nat Cell Biol</source><year>2002</year><volume>4</volume><fpage>160</fpage><lpage>164</lpage><pub-id pub-id-type="doi">10.1038/ncb841</pub-id><pub-id pub-id-type="pmid">11813001</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chau</surname><given-names>KY</given-names></name><name><surname>Ching</surname><given-names>HL</given-names></name><name><surname>Schapira</surname><given-names>AH</given-names></name><name><surname>Cooper</surname><given-names>JM</given-names></name></person-group><article-title>Relationship between &#x003b1; synuclein
phosphorylation, proteasomal inhibition and cell death: relevance to
Parkinson&#x02019;s disease pathogenesis</article-title><source>J Neurochem</source><year>2009</year><volume>110</volume><fpage>1005</fpage><lpage>1013</lpage><pub-id pub-id-type="doi">10.1111/j.1471-4159.2009.06191.x</pub-id><pub-id pub-id-type="pmid">19493164</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Feany</surname><given-names>MB</given-names></name></person-group><article-title>&#x003b1;-Synuclein phosphorylation controls
neurotoxicity and inclusion formation in a Drosophila model of
Parkinson disease</article-title><source>Nat Neurosci</source><year>2005</year><volume>8</volume><fpage>657</fpage><lpage>663</lpage><pub-id pub-id-type="doi">10.1038/nn1443</pub-id><pub-id pub-id-type="pmid">15834418</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Periquet</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Negro</surname><given-names>A</given-names></name><name><surname>McLean</surname><given-names>PJ</given-names></name><name><surname>Hyman</surname><given-names>BT</given-names></name><name><surname>Feany</surname><given-names>MB</given-names></name></person-group><article-title>Tyrosine and serine phosphorylation of
&#x003b1;-synuclein have opposing effects on neurotoxicity and soluble
oligomer formation</article-title><source>J Clin Invest</source><year>2009</year><volume>119</volume><fpage>3257</fpage><lpage>3265</lpage><pub-id pub-id-type="doi">10.1172/JCI35314</pub-id><pub-id pub-id-type="pmid">19855133</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>KW</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Junn</surname><given-names>E</given-names></name><name><surname>Im</surname><given-names>JY</given-names></name><name><surname>Grosso</surname><given-names>H</given-names></name><name><surname>Sonsalla</surname><given-names>PK</given-names></name><name><surname>Feng</surname><given-names>X</given-names></name><name><surname>Ray</surname><given-names>N</given-names></name><name><surname>Fernandez</surname><given-names>JR</given-names></name><name><surname>Chao</surname><given-names>Y</given-names></name></person-group><article-title>Enhanced phosphatase activity attenuates
&#x003b1;-synucleinopathy in a mouse model</article-title><source>J Neurosci</source><year>2011</year><volume>31</volume><fpage>6963</fpage><lpage>6971</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.6513-10.2011</pub-id><pub-id pub-id-type="pmid">21562258</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paleologou</surname><given-names>KE</given-names></name><name><surname>Oueslati</surname><given-names>A</given-names></name><name><surname>Shakked</surname><given-names>G</given-names></name><name><surname>Rospigliosi</surname><given-names>CC</given-names></name><name><surname>Kim</surname><given-names>HY</given-names></name><name><surname>Lamberto</surname><given-names>GR</given-names></name><name><surname>Fernandez</surname><given-names>CO</given-names></name><name><surname>Schmid</surname><given-names>A</given-names></name><name><surname>Chegini</surname><given-names>F</given-names></name><name><surname>Gai</surname><given-names>WP</given-names></name><name><surname>Chiappe</surname><given-names>D</given-names></name><name><surname>Moniatte</surname><given-names>M</given-names></name><name><surname>Schneider</surname><given-names>BL</given-names></name><name><surname>Aebischer</surname><given-names>P</given-names></name><name><surname>Eliezer</surname><given-names>D</given-names></name><name><surname>Zweckstetter</surname><given-names>M</given-names></name><name><surname>Masliah</surname><given-names>E</given-names></name><name><surname>Lashuel</surname><given-names>HA</given-names></name></person-group><article-title>Phosphorylation at S87 is enhanced in
synucleinopathies, inhibits &#x003b1;-synuclein oligomerization, and
influences synuclein-membrane interactions</article-title><source>J Neurosci</source><year>2010</year><volume>30</volume><fpage>3184</fpage><lpage>3198</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.5922-09.2010</pub-id><pub-id pub-id-type="pmid">20203178</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schreurs</surname><given-names>S</given-names></name><name><surname>Gerard</surname><given-names>M</given-names></name><name><surname>Derua</surname><given-names>R</given-names></name><name><surname>Waelkens</surname><given-names>E</given-names></name><name><surname>Taymans</surname><given-names>JM</given-names></name><name><surname>Baekelandt</surname><given-names>V</given-names></name><name><surname>Engelborghs</surname><given-names>Y</given-names></name></person-group><article-title>In vitro phosphorylation does not influence
the aggregation kinetics of WT &#x003b1;-synuclein in contrast to its
phosphorylation mutants</article-title><source>Int J Mol Sci</source><year>2014</year><volume>15</volume><fpage>1040</fpage><lpage>1067</lpage><pub-id pub-id-type="doi">10.3390/ijms15011040</pub-id><pub-id pub-id-type="pmid">24434619</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waxman</surname><given-names>EA</given-names></name><name><surname>Giasson</surname><given-names>BI</given-names></name></person-group><article-title>Specificity and regulation of casein
kinase-mediated phosphorylation of alpha-synuclein</article-title><source>J Neuropathol Exp Neurol</source><year>2008</year><volume>67</volume><fpage>402</fpage><lpage>416</lpage><pub-id pub-id-type="doi">10.1097/NEN.0b013e3186fc995</pub-id><pub-id pub-id-type="pmid">18451726</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beach</surname><given-names>TG</given-names></name><name><surname>Adler</surname><given-names>CH</given-names></name><name><surname>Lue</surname><given-names>LF</given-names></name><name><surname>Sue</surname><given-names>LI</given-names></name><name><surname>Bachalakuri</surname><given-names>J</given-names></name><name><surname>Henry-Watson</surname><given-names>J</given-names></name><name><surname>Sasse</surname><given-names>J</given-names></name><name><surname>Boyer</surname><given-names>S</given-names></name><name><surname>Shirohi</surname><given-names>S</given-names></name><name><surname>Brooks</surname><given-names>R</given-names></name><name><surname>Eschbacher</surname><given-names>J</given-names></name><name><surname>White</surname><given-names>CL</given-names><suffix>3rd</suffix></name><name><surname>Akiyama</surname><given-names>H</given-names></name><name><surname>Caviness</surname><given-names>J</given-names></name><name><surname>Shill</surname><given-names>HA</given-names></name><name><surname>Connor</surname><given-names>DJ</given-names></name><name><surname>Sabbagh</surname><given-names>MN</given-names></name><name><surname>Walker</surname><given-names>DG</given-names></name><collab>Arizona Parkinson&#x02019;s Disease
Consortium</collab></person-group><article-title>Unified staging system for Lewy body
disorders: correlation with nigrostriatal degeneration, cognitive
impairment and motor dysfunction</article-title><source>Acta Neuropathol</source><year>2009</year><volume>117</volume><fpage>613</fpage><lpage>634</lpage><pub-id pub-id-type="doi">10.1007/s00401-009-0538-8</pub-id><pub-id pub-id-type="pmid">19399512</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Obi</surname><given-names>K</given-names></name><name><surname>Akiyama</surname><given-names>H</given-names></name><name><surname>Kondo</surname><given-names>H</given-names></name><name><surname>Shimomura</surname><given-names>Y</given-names></name><name><surname>Hasegawa</surname><given-names>M</given-names></name><name><surname>Iwatsubo</surname><given-names>T</given-names></name><name><surname>Mizuno</surname><given-names>Y</given-names></name><name><surname>Mochizuki</surname><given-names>H</given-names></name></person-group><article-title>Relationship of phosphorylated &#x003b1;-synuclein
and tau accumulation to A&#x003b2; deposition in the cerebral cortex of
dementia with Lewy bodies</article-title><source>Exp Neurol</source><year>2008</year><volume>210</volume><fpage>409</fpage><lpage>420</lpage><pub-id pub-id-type="doi">10.1016/j.expneurol.2007.11.019</pub-id><pub-id pub-id-type="pmid">18164295</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walker</surname><given-names>DG</given-names></name><name><surname>Lue</surname><given-names>LF</given-names></name><name><surname>Adler</surname><given-names>CH</given-names></name><name><surname>Shill</surname><given-names>HA</given-names></name><name><surname>Caviness</surname><given-names>JN</given-names></name><name><surname>Sabbagh</surname><given-names>MN</given-names></name><name><surname>Akiyama</surname><given-names>H</given-names></name><name><surname>Serrano</surname><given-names>GE</given-names></name><name><surname>Sue</surname><given-names>LI</given-names></name><name><surname>Beach</surname><given-names>TG</given-names></name><collab>Arizona Parkinson Disease
Consortium</collab></person-group><article-title>Changes in properties of serine 129
phosphorylated &#x003b1;-synuclein with progression of Lewy-type
histopathology in human brains</article-title><source>Exp Neurol</source><year>2013</year><volume>240</volume><fpage>190</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.1016/j.expneurol.2012.11.020</pub-id><pub-id pub-id-type="pmid">23201181</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miners</surname><given-names>JS</given-names></name><name><surname>van Helmond</surname><given-names>Z</given-names></name><name><surname>Raiker</surname><given-names>M</given-names></name><name><surname>Love</surname><given-names>S</given-names></name><name><surname>Kehoe</surname><given-names>PG</given-names></name></person-group><article-title>ACE variants and association with brain A&#x003b2;
levels in Alzheimer&#x02019;s disease</article-title><source>Am J Transl Res</source><year>2010</year><volume>3</volume><fpage>73</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">21139807</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tayler</surname><given-names>H</given-names></name><name><surname>Fraser</surname><given-names>T</given-names></name><name><surname>Miners</surname><given-names>JS</given-names></name><name><surname>Kehoe</surname><given-names>PG</given-names></name><name><surname>Love</surname><given-names>S</given-names></name></person-group><article-title>Oxidative balance in Alzheimer&#x02019;s disease:
relationship to APOE, Braak tangle stage, and the concentrations of
soluble and insoluble amyloid-&#x003b2;</article-title><source>J Alzheimers Dis</source><year>2010</year><volume>22</volume><fpage>1363</fpage><lpage>1373</lpage><pub-id pub-id-type="pmid">20930272</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Helmond</surname><given-names>Z</given-names></name><name><surname>Miners</surname><given-names>JS</given-names></name><name><surname>Kehoe</surname><given-names>PG</given-names></name><name><surname>Love</surname><given-names>S</given-names></name></person-group><article-title>Higher soluble amyloid &#x003b2; concentration in
frontal cortex of young adults than in normal elderly or Alzheimer&#x02019;s
disease</article-title><source>Brain Pathol</source><year>2010</year><volume>20</volume><fpage>787</fpage><lpage>793</lpage><pub-id pub-id-type="doi">10.1111/j.1750-3639.2010.00374.x</pub-id><pub-id pub-id-type="pmid">20175777</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miners</surname><given-names>JS</given-names></name><name><surname>Jones</surname><given-names>R</given-names></name><name><surname>Love</surname><given-names>S</given-names></name></person-group><article-title>Differential changes in A&#x003b2;42 and A&#x003b2;40 with
age</article-title><source>J Alzheimers Dis</source><year>2014</year><volume>40</volume><fpage>727</fpage><lpage>735</lpage><pub-id pub-id-type="pmid">24503618</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKeith</surname><given-names>IG</given-names></name><name><surname>Dickson</surname><given-names>D</given-names></name><name><surname>Lowe</surname><given-names>J</given-names></name><name><surname>Emre</surname><given-names>M</given-names></name><name><surname>O'Brien</surname><given-names>J</given-names></name><name><surname>Feldman</surname><given-names>H</given-names></name><name><surname>Cummings</surname><given-names>J</given-names></name><name><surname>Duda</surname><given-names>J</given-names></name><name><surname>Lippa</surname><given-names>C</given-names></name><name><surname>Perry</surname><given-names>E</given-names></name><name><surname>Aarsland</surname><given-names>D</given-names></name><name><surname>Arai</surname><given-names>H</given-names></name><name><surname>Ballard</surname><given-names>CG</given-names></name><name><surname>Boeve</surname><given-names>B</given-names></name><name><surname>Burn</surname><given-names>DJ</given-names></name><name><surname>Costa</surname><given-names>D</given-names></name><name><surname>Del Ser</surname><given-names>T</given-names></name><name><surname>Dubois</surname><given-names>B</given-names></name><name><surname>Galasko</surname><given-names>D</given-names></name><name><surname>Gauthier</surname><given-names>S</given-names></name><name><surname>Goetz</surname><given-names>CG</given-names></name><name><surname>Gomez-Tortosa</surname><given-names>E</given-names></name><name><surname>Halliday</surname><given-names>G</given-names></name><name><surname>Hansen</surname><given-names>LA</given-names></name><name><surname>Hardy</surname><given-names>J</given-names></name><name><surname>Iwatsubo</surname><given-names>T</given-names></name><name><surname>Kalaria</surname><given-names>RN</given-names></name><name><surname>Kaufer</surname><given-names>D</given-names></name><name><surname>Kenny</surname><given-names>RA</given-names></name><name><surname>Korczyn</surname><given-names>A</given-names></name><etal/></person-group><article-title>Diagnosis and management of dementia with
Lewy bodies: third report of the DLB consortium</article-title><source>Neurology</source><year>2005</year><volume>65</volume><fpage>1863</fpage><lpage>1872</lpage><pub-id pub-id-type="doi">10.1212/01.wnl.0000187889.17253.b1</pub-id><pub-id pub-id-type="pmid">16237129</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montine</surname><given-names>TJ</given-names></name><name><surname>Phelps</surname><given-names>CH</given-names></name><name><surname>Beach</surname><given-names>TG</given-names></name><name><surname>Bigio</surname><given-names>EH</given-names></name><name><surname>Cairns</surname><given-names>NJ</given-names></name><name><surname>Dickson</surname><given-names>DW</given-names></name><name><surname>Duyckaerts</surname><given-names>C</given-names></name><name><surname>Frosch</surname><given-names>MP</given-names></name><name><surname>Masliah</surname><given-names>E</given-names></name><name><surname>Mirra</surname><given-names>SS</given-names></name><name><surname>Nelson</surname><given-names>PT</given-names></name><name><surname>Schneider</surname><given-names>JA</given-names></name><name><surname>Thal</surname><given-names>DR</given-names></name><name><surname>Trojanowski</surname><given-names>JQ</given-names></name><name><surname>Vinters</surname><given-names>HV</given-names></name><name><surname>Hyman</surname><given-names>BT</given-names></name><collab>National Institute on Aging, Alzheimer&#x02019;s
Association</collab></person-group><article-title>National Institute on Aging&#x02013;Alzheimer&#x02019;s
Association guidelines for the neuropathologic assessment of
Alzheimer&#x02019;s disease: a practical approach</article-title><source>Acta Neuropathol</source><year>2012</year><volume>123</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1007/s00401-011-0910-3</pub-id><pub-id pub-id-type="pmid">22101365</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miners</surname><given-names>JS</given-names></name><name><surname>Morris</surname><given-names>S</given-names></name><name><surname>Love</surname><given-names>S</given-names></name><name><surname>Kehoe</surname><given-names>PG</given-names></name></person-group><article-title>Accumulation of insoluble amyloid-&#x003b2; in Down&#x02019;s
syndrome is associated with increased BACE-1 and neprilysin
activities</article-title><source>J Alzheimers Dis</source><year>2011</year><volume>23</volume><fpage>101</fpage><lpage>108</lpage><pub-id pub-id-type="pmid">20930275</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miners</surname><given-names>JS</given-names></name><name><surname>Moulding</surname><given-names>H</given-names></name><name><surname>de Silva</surname><given-names>R</given-names></name><name><surname>Love</surname><given-names>S</given-names></name></person-group><article-title>Reduced vascular endothelial growth factor
and capillary density in the occipital cortex in dementia with Lewy
bodies</article-title><source>Brain Pathol</source><year>2014</year><volume>24</volume><fpage>334</fpage><lpage>343</lpage><pub-id pub-id-type="doi">10.1111/bpa.12130</pub-id><pub-id pub-id-type="pmid">24521289</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>G</given-names></name><name><surname>Tanaka</surname><given-names>M</given-names></name><name><surname>Park</surname><given-names>K</given-names></name><name><surname>Lee</surname><given-names>SS</given-names></name><name><surname>Kim</surname><given-names>YM</given-names></name><name><surname>Junn</surname><given-names>E</given-names></name><name><surname>Lee</surname><given-names>SH</given-names></name><name><surname>Mouradian</surname><given-names>MM</given-names></name></person-group><article-title>Casein kinase II-mediated phosphorylation
regulates &#x003b1;-synuclein/synphilin-1 interaction and inclusion body
formation</article-title><source>J Biol Chem</source><year>2004</year><volume>279</volume><fpage>6834</fpage><lpage>6839</lpage><pub-id pub-id-type="doi">10.1074/jbc.M312760200</pub-id><pub-id pub-id-type="pmid">14645218</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okochi</surname><given-names>M</given-names></name><name><surname>Walter</surname><given-names>J</given-names></name><name><surname>Koyama</surname><given-names>A</given-names></name><name><surname>Nakajo</surname><given-names>S</given-names></name><name><surname>Baba</surname><given-names>M</given-names></name><name><surname>Iwatsubo</surname><given-names>T</given-names></name><name><surname>Meijer</surname><given-names>L</given-names></name><name><surname>Kahle</surname><given-names>PJ</given-names></name><name><surname>Haass</surname><given-names>C</given-names></name></person-group><article-title>Constitutive phosphorylation of the
Parkinson&#x02019;s disease associated &#x003b1;-synuclein</article-title><source>J Biol Chem</source><year>2000</year><volume>275</volume><fpage>390</fpage><lpage>397</lpage><pub-id pub-id-type="doi">10.1074/jbc.275.1.390</pub-id><pub-id pub-id-type="pmid">10617630</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barua</surname><given-names>NU</given-names></name><name><surname>Miners</surname><given-names>JS</given-names></name><name><surname>Bienemann</surname><given-names>AS</given-names></name><name><surname>Wyatt</surname><given-names>MJ</given-names></name><name><surname>Welser</surname><given-names>K</given-names></name><name><surname>Tabor</surname><given-names>AB</given-names></name><name><surname>Hailes</surname><given-names>HC</given-names></name><name><surname>Love</surname><given-names>S</given-names></name><name><surname>Gill</surname><given-names>SS</given-names></name></person-group><article-title>Convection-enhanced delivery of neprilysin: a
novel amyloid-&#x003b2;-degrading therapeutic strategy</article-title><source>J Alzheimers Dis</source><year>2012</year><volume>32</volume><fpage>43</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">22751177</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qiu</surname><given-names>WQ</given-names></name><name><surname>Ye</surname><given-names>Z</given-names></name><name><surname>Kholodenko</surname><given-names>D</given-names></name><name><surname>Seubert</surname><given-names>P</given-names></name><name><surname>Selkoe</surname><given-names>DJ</given-names></name></person-group><article-title>Degradation of amyloid &#x003b2;-protein by a
metalloprotease secreted by microglia and other neural and non-neural
cells</article-title><source>J Biol Chem</source><year>1997</year><volume>272</volume><fpage>6641</fpage><lpage>6646</lpage><pub-id pub-id-type="doi">10.1074/jbc.272.10.6641</pub-id><pub-id pub-id-type="pmid">9045694</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ashby</surname><given-names>EL</given-names></name><name><surname>Kehoe</surname><given-names>PG</given-names></name><name><surname>Love</surname><given-names>S</given-names></name></person-group><article-title>Kallikrein-related peptidase 6 in Alzheimer&#x02019;s
disease and vascular dementia</article-title><source>Brain Res</source><year>2010</year><volume>1363</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1016/j.brainres.2010.09.017</pub-id><pub-id pub-id-type="pmid">20846516</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chalmers</surname><given-names>K</given-names></name><name><surname>Wilcock</surname><given-names>GK</given-names></name><name><surname>Love</surname><given-names>S</given-names></name></person-group><article-title><italic>APOE</italic> &#x003b5;4 influences the pathological
phenotype of Alzheimer&#x02019;s disease by favouring cerebrovascular over
parenchymal accumulation of A&#x003b2; protein</article-title><source>Neuropathol Appl Neurobiol</source><year>2003</year><volume>29</volume><fpage>231</fpage><lpage>238</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2990.2003.00457.x</pub-id><pub-id pub-id-type="pmid">12787320</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chalmers</surname><given-names>KA</given-names></name><name><surname>Wilcock</surname><given-names>GK</given-names></name><name><surname>Vinters</surname><given-names>HV</given-names></name><name><surname>Perry</surname><given-names>EK</given-names></name><name><surname>Perry</surname><given-names>R</given-names></name><name><surname>Ballard</surname><given-names>CG</given-names></name><name><surname>Love</surname><given-names>S</given-names></name></person-group><article-title>Cholinesterase inhibitors may increase
phosphorylated tau in Alzheimer&#x02019;s disease</article-title><source>J Neurol</source><year>2009</year><volume>256</volume><fpage>717</fpage><lpage>720</lpage><pub-id pub-id-type="doi">10.1007/s00415-009-5000-2</pub-id><pub-id pub-id-type="pmid">19240967</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Helmond</surname><given-names>Z</given-names></name><name><surname>Heesom</surname><given-names>K</given-names></name><name><surname>Love</surname><given-names>S</given-names></name></person-group><article-title>Characterisation of two antibodies to
oligomeric A&#x003b2; and their use in ELISAs on human brain tissue
homogenates</article-title><source>J Neurosci Methods</source><year>2009</year><volume>176</volume><fpage>206</fpage><lpage>212</lpage><pub-id pub-id-type="doi">10.1016/j.jneumeth.2008.09.002</pub-id><pub-id pub-id-type="pmid">18824027</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colom-Cadena</surname><given-names>M</given-names></name><name><surname>Gelpi</surname><given-names>E</given-names></name><name><surname>Charif</surname><given-names>S</given-names></name><name><surname>Belbin</surname><given-names>O</given-names></name><name><surname>Blesa</surname><given-names>R</given-names></name><name><surname>Mart&#x000ed;</surname><given-names>MJ</given-names></name><name><surname>Clarim&#x000f3;n</surname><given-names>J</given-names></name><name><surname>Lle&#x000f3;</surname><given-names>A</given-names></name></person-group><article-title>Confluence of &#x003b1;-synuclein, tau, and &#x003b2;-amyloid
pathologies in dementia with Lewy bodies</article-title><source>J Neuropathol Exp Neurol</source><year>2013</year><volume>72</volume><fpage>1203</fpage><lpage>1212</lpage><pub-id pub-id-type="doi">10.1097/NEN.0000000000000018</pub-id><pub-id pub-id-type="pmid">24226269</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Compta</surname><given-names>Y</given-names></name><name><surname>Parkkinen</surname><given-names>L</given-names></name><name><surname>O'Sullivan</surname><given-names>SS</given-names></name><name><surname>Vandrovcova</surname><given-names>J</given-names></name><name><surname>Holton</surname><given-names>JL</given-names></name><name><surname>Collins</surname><given-names>C</given-names></name><name><surname>Lashley</surname><given-names>T</given-names></name><name><surname>Kallis</surname><given-names>C</given-names></name><name><surname>Williams</surname><given-names>DR</given-names></name><name><surname>de Silva</surname><given-names>R</given-names></name><name><surname>Lees</surname><given-names>AJ</given-names></name><name><surname>Revesz</surname><given-names>T</given-names></name></person-group><article-title>Lewy-and Alzheimer-type pathologies in
Parkinson&#x02019;s disease dementia: which is more important?</article-title><source>Brain</source><year>2011</year><volume>134</volume><fpage>1493</fpage><lpage>1505</lpage><pub-id pub-id-type="doi">10.1093/brain/awr031</pub-id><pub-id pub-id-type="pmid">21596773</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dickson</surname><given-names>DW</given-names></name><name><surname>Fujishiro</surname><given-names>H</given-names></name><name><surname>Orr</surname><given-names>C</given-names></name><name><surname>DelleDonne</surname><given-names>A</given-names></name><name><surname>Josephs</surname><given-names>KA</given-names></name><name><surname>Frigerio</surname><given-names>R</given-names></name><name><surname>Burnett</surname><given-names>M</given-names></name><name><surname>Parisi</surname><given-names>JE</given-names></name><name><surname>Klos</surname><given-names>KJ</given-names></name><name><surname>Ahlskog</surname><given-names>JE</given-names></name></person-group><article-title>Neuropathology of non-motor features of
Parkinson disease</article-title><source>Parkinsonism Relat Disord</source><year>2009</year><volume>15</volume><fpage>S1</fpage><lpage>S5</lpage><pub-id pub-id-type="doi">10.1016/S1353-8020(09)70769-2</pub-id><pub-id pub-id-type="pmid">20082965</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leverenz</surname><given-names>JB</given-names></name><name><surname>Fishel</surname><given-names>MA</given-names></name><name><surname>Peskind</surname><given-names>ER</given-names></name><name><surname>Montine</surname><given-names>TJ</given-names></name><name><surname>Nochlin</surname><given-names>D</given-names></name><name><surname>Steinbart</surname><given-names>E</given-names></name><name><surname>Raskind</surname><given-names>MA</given-names></name><name><surname>Schellenberg</surname><given-names>GD</given-names></name><name><surname>Bird</surname><given-names>TD</given-names></name><name><surname>Tsuang</surname><given-names>D</given-names></name></person-group><article-title>Lewy body pathology in familial Alzheimer
disease: evidence for disease-and mutation-specific pathologic
phenotype</article-title><source>Arch Neurol</source><year>2006</year><volume>63</volume><fpage>370</fpage><pub-id pub-id-type="doi">10.1001/archneur.63.3.370</pub-id><pub-id pub-id-type="pmid">16533963</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenberg</surname><given-names>CK</given-names></name><name><surname>Pericak-Vance</surname><given-names>MA</given-names></name><name><surname>Saunders</surname><given-names>AM</given-names></name><name><surname>Gilbert</surname><given-names>JR</given-names></name><name><surname>Gaskell</surname><given-names>PC</given-names></name><name><surname>Hulette</surname><given-names>CM</given-names></name></person-group><article-title>Lewy body and Alzheimer pathology in a family
with the amyloid-&#x003b2; precursor protein APP717 gene
mutation</article-title><source>Acta Neuropathol</source><year>2000</year><volume>100</volume><fpage>145</fpage><lpage>152</lpage><pub-id pub-id-type="doi">10.1007/s004019900155</pub-id><pub-id pub-id-type="pmid">10963361</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurata</surname><given-names>T</given-names></name><name><surname>Kawarabayashi</surname><given-names>T</given-names></name><name><surname>Murakami</surname><given-names>T</given-names></name><name><surname>Miyazaki</surname><given-names>K</given-names></name><name><surname>Morimoto</surname><given-names>N</given-names></name><name><surname>Hta</surname><given-names>Y</given-names></name><name><surname>Takehisa</surname><given-names>Y</given-names></name><name><surname>Nagai</surname><given-names>M</given-names></name><name><surname>Ikeda</surname><given-names>M</given-names></name><name><surname>Matsubara</surname><given-names>E</given-names></name><name><surname>Westaway</surname><given-names>D</given-names></name><name><surname>Hyslop</surname><given-names>PS</given-names></name><name><surname>Harigaya</surname><given-names>Y</given-names></name><name><surname>Kamiya</surname><given-names>T</given-names></name><name><surname>Shoji</surname><given-names>M</given-names></name><name><surname>Abe</surname><given-names>K</given-names></name></person-group><article-title>Enhanced accumulation of phosphorylated
alpha-synuclein in double transgenic mice expressing mutant
beta-amyloid precursor protein and presenilin-1</article-title><source>J Neurosci Res</source><year>2007</year><volume>85</volume><fpage>2246</fpage><lpage>2252</lpage><pub-id pub-id-type="doi">10.1002/jnr.21352</pub-id><pub-id pub-id-type="pmid">17526016</pub-id></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pappot</surname><given-names>H</given-names></name><name><surname>Skov</surname><given-names>BG</given-names></name><name><surname>Pyke</surname><given-names>C</given-names></name><name><surname>Grondahl-Hansen</surname><given-names>J</given-names></name></person-group><article-title>Levels of plasminogen activator inhibitor
type 1 and urokinase plasminogen activator receptor in non-small cell
lung cancer as measured by quantitative ELISA and semiquantitative
immunohistochemistry</article-title><source>Lung Cancer</source><year>1997</year><volume>17</volume><fpage>197</fpage><lpage>209</lpage><pub-id pub-id-type="doi">10.1016/S0169-5002(97)00032-9</pub-id><pub-id pub-id-type="pmid">9237155</pub-id></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Witte</surname><given-names>H</given-names></name><name><surname>Pappot</surname><given-names>H</given-names></name><name><surname>Brunner</surname><given-names>N</given-names></name><name><surname>Grondahl-Hansen</surname><given-names>J</given-names></name><name><surname>Hoyer-Hansen</surname><given-names>G</given-names></name><name><surname>Behrendt</surname><given-names>N</given-names></name><name><surname>Guldhammer-Skov</surname><given-names>B</given-names></name><name><surname>Sweep</surname><given-names>F</given-names></name><name><surname>Benraad</surname><given-names>T</given-names></name><name><surname>Dano</surname><given-names>K</given-names></name></person-group><article-title>ELISA for complexes between urokinase-type
plasminogen activator and its receptor in lung cancer tissue
extracts</article-title><source>Int J Cancer</source><year>1997</year><volume>72</volume><fpage>416</fpage><lpage>423</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1097-0215(19970729)72:3&#x0003c;416::AID-IJC8&#x0003e;3.0.CO;2-S</pub-id><pub-id pub-id-type="pmid">9247284</pub-id></element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrier</surname><given-names>CM</given-names></name><name><surname>de Witte</surname><given-names>HH</given-names></name><name><surname>Straatman</surname><given-names>H</given-names></name><name><surname>van Tienoven</surname><given-names>DH</given-names></name><name><surname>van Geloof</surname><given-names>WL</given-names></name><name><surname>Rietveld</surname><given-names>FJ</given-names></name><name><surname>Sweep</surname><given-names>CG</given-names></name><name><surname>Ruiter</surname><given-names>DJ</given-names></name><name><surname>van Muijen</surname><given-names>GN</given-names></name></person-group><article-title>Comparison of immunohistochemistry with
immunoassay (ELISA) for the detection of components of the plasminogen
activation system in human tumour tissue</article-title><source>Br J Cancer</source><year>1999</year><volume>79</volume><fpage>1534</fpage><lpage>1541</lpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6690245</pub-id><pub-id pub-id-type="pmid">10188903</pub-id></element-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mandal</surname><given-names>PK</given-names></name><name><surname>Pettegrew</surname><given-names>JW</given-names></name><name><surname>Masliah</surname><given-names>E</given-names></name><name><surname>Hamilton</surname><given-names>RL</given-names></name><name><surname>Mandal</surname><given-names>R</given-names></name></person-group><article-title>Interaction between A&#x003b2; peptide and &#x003b1;
synuclein: molecular mechanisms in overlapping pathology of
Alzheimer&#x02019;s and Parkinson&#x02019;s in dementia with Lewy body
disease</article-title><source>Neurochem Res</source><year>2006</year><volume>31</volume><fpage>1153</fpage><lpage>1162</lpage><pub-id pub-id-type="doi">10.1007/s11064-006-9140-9</pub-id><pub-id pub-id-type="pmid">16947080</pub-id></element-citation></ref><ref id="CR72"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bate</surname><given-names>C</given-names></name><name><surname>Gentleman</surname><given-names>S</given-names></name><name><surname>Williams</surname><given-names>A</given-names></name></person-group><article-title>&#x003b1;-Synuclein induced synapse damage is
enhanced by amyloid-beta(1&#x02013;42)</article-title><source>Mol Neurodegener</source><year>2010</year><volume>5</volume><fpage>55</fpage><pub-id pub-id-type="doi">10.1186/1750-1326-5-55</pub-id><pub-id pub-id-type="pmid">21138585</pub-id></element-citation></ref><ref id="CR73"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pronin</surname><given-names>AN</given-names></name><name><surname>Morris</surname><given-names>AJ</given-names></name><name><surname>Surguchov</surname><given-names>A</given-names></name><name><surname>Benovic</surname><given-names>JL</given-names></name></person-group><article-title>Synucleins are a novel class of substrates
for G protein-coupled receptor kinases</article-title><source>J Biol Chem</source><year>2000</year><volume>275</volume><fpage>26515</fpage><lpage>26522</lpage><pub-id pub-id-type="doi">10.1074/jbc.M003542200</pub-id><pub-id pub-id-type="pmid">10852916</pub-id></element-citation></ref><ref id="CR74"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qing</surname><given-names>H</given-names></name><name><surname>Wong</surname><given-names>W</given-names></name><name><surname>McGeer</surname><given-names>EG</given-names></name><name><surname>McGeer</surname><given-names>PL</given-names></name></person-group><article-title>Lrrk2 phosphorylates &#x003b1; synuclein at serine
129: Parkinson disease implications</article-title><source>Biochem Biophys Res Commun</source><year>2009</year><volume>387</volume><fpage>149</fpage><lpage>152</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2009.06.142</pub-id><pub-id pub-id-type="pmid">19576176</pub-id></element-citation></ref><ref id="CR75"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inglis</surname><given-names>KJ</given-names></name><name><surname>Chereau</surname><given-names>D</given-names></name><name><surname>Brigham</surname><given-names>EF</given-names></name><name><surname>Chiou</surname><given-names>SS</given-names></name><name><surname>Schobel</surname><given-names>S</given-names></name><name><surname>Frigon</surname><given-names>NL</given-names></name><name><surname>Yu</surname><given-names>M</given-names></name><name><surname>Caccavello</surname><given-names>RJ</given-names></name><name><surname>Nelson</surname><given-names>S</given-names></name><name><surname>Motter</surname><given-names>R</given-names></name><name><surname>Wright</surname><given-names>S</given-names></name><name><surname>Chian</surname><given-names>D</given-names></name><name><surname>Santiago</surname><given-names>P</given-names></name><name><surname>Soriano</surname><given-names>F</given-names></name><name><surname>Ramos</surname><given-names>C</given-names></name><name><surname>Powell</surname><given-names>K</given-names></name><name><surname>Goldstein</surname><given-names>JM</given-names></name><name><surname>Babcock</surname><given-names>M</given-names></name><name><surname>Yednock</surname><given-names>T</given-names></name><name><surname>Bard</surname><given-names>F</given-names></name><name><surname>Basi</surname><given-names>GS</given-names></name><name><surname>Sham</surname><given-names>H</given-names></name><name><surname>Chilcote</surname><given-names>TJ</given-names></name><name><surname>McConlogue</surname><given-names>L</given-names></name><name><surname>Griswold-Prenner</surname><given-names>I</given-names></name><name><surname>Anderson</surname><given-names>JP</given-names></name></person-group><article-title>Polo-like kinase 2 (PLK2) phosphorylates
&#x003b1;-synuclein at serine 129 in central nervous system</article-title><source>J Biol Chem</source><year>2009</year><volume>284</volume><fpage>2598</fpage><lpage>2602</lpage><pub-id pub-id-type="doi">10.1074/jbc.C800206200</pub-id><pub-id pub-id-type="pmid">19004816</pub-id></element-citation></ref><ref id="CR76"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mbefo</surname><given-names>MK</given-names></name><name><surname>Paleologou</surname><given-names>KE</given-names></name><name><surname>Boucharaba</surname><given-names>A</given-names></name><name><surname>Oueslati</surname><given-names>A</given-names></name><name><surname>Schell</surname><given-names>H</given-names></name><name><surname>Fournier</surname><given-names>M</given-names></name><name><surname>Olschewski</surname><given-names>D</given-names></name><name><surname>Yin</surname><given-names>GW</given-names></name><name><surname>Zweckstetter</surname><given-names>M</given-names></name><name><surname>Masliah</surname><given-names>E</given-names></name><name><surname>Kahle</surname><given-names>PJ</given-names></name><name><surname>Hirling</surname><given-names>H</given-names></name><name><surname>Lashuel</surname><given-names>HA</given-names></name></person-group><article-title>Phosphorylation of synucleins by members of
the Polo-like kinase family</article-title><source>J Biol Chem</source><year>2010</year><volume>285</volume><fpage>2807</fpage><lpage>2822</lpage><pub-id pub-id-type="doi">10.1074/jbc.M109.081950</pub-id><pub-id pub-id-type="pmid">19889641</pub-id></element-citation></ref><ref id="CR77"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yasojima</surname><given-names>K</given-names></name><name><surname>Kuret</surname><given-names>J</given-names></name><name><surname>DeMaggio</surname><given-names>AJ</given-names></name><name><surname>McGeer</surname><given-names>E</given-names></name><name><surname>McGeer</surname><given-names>PL</given-names></name></person-group><article-title>Casein kinase 1 delta mRNA is upregulated in
Alzheimer disease brain</article-title><source>Brain Res</source><year>2000</year><volume>865</volume><fpage>116</fpage><lpage>120</lpage><pub-id pub-id-type="doi">10.1016/S0006-8993(00)02200-9</pub-id><pub-id pub-id-type="pmid">10814741</pub-id></element-citation></ref><ref id="CR78"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baig</surname><given-names>S</given-names></name><name><surname>van Helmond</surname><given-names>Z</given-names></name><name><surname>Love</surname><given-names>S</given-names></name></person-group><article-title>Tau hyperphosphorylation affects Smad 2/3
translocation</article-title><source>Neuroscience</source><year>2009</year><volume>163</volume><fpage>561</fpage><lpage>570</lpage><pub-id pub-id-type="doi">10.1016/j.neuroscience.2009.06.045</pub-id><pub-id pub-id-type="pmid">19555739</pub-id></element-citation></ref><ref id="CR79"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>G&#x000f6;tz</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>F</given-names></name><name><surname>Van Dorpe</surname><given-names>J</given-names></name><name><surname>Nitsch</surname><given-names>R</given-names></name></person-group><article-title>Formation of neurofibrillary tangles in P301L
tau transgenic mice induced by A&#x003b2;42 fibrils</article-title><source>Science</source><year>2001</year><volume>293</volume><fpage>1491</fpage><lpage>1495</lpage><pub-id pub-id-type="doi">10.1126/science.1062097</pub-id><pub-id pub-id-type="pmid">11520988</pub-id></element-citation></ref><ref id="CR80"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lewis</surname><given-names>J</given-names></name><name><surname>McGowan</surname><given-names>E</given-names></name><name><surname>Rockwood</surname><given-names>J</given-names></name><name><surname>Melrose</surname><given-names>H</given-names></name><name><surname>Nacharaju</surname><given-names>P</given-names></name><name><surname>Van Slegtenhorst</surname><given-names>M</given-names></name><name><surname>Gwinn-Hardy</surname><given-names>K</given-names></name><name><surname>Murphy</surname><given-names>MP</given-names></name><name><surname>Baker</surname><given-names>M</given-names></name><name><surname>Yu</surname><given-names>X</given-names></name><name><surname>Duff</surname><given-names>K</given-names></name><name><surname>Hardy</surname><given-names>J</given-names></name><name><surname>Corral</surname><given-names>A</given-names></name><name><surname>Lin</surname><given-names>WL</given-names></name><name><surname>Yen</surname><given-names>SH</given-names></name><name><surname>Dickson</surname><given-names>DW</given-names></name><name><surname>Davies</surname><given-names>P</given-names></name><name><surname>Hutton</surname><given-names>M</given-names></name></person-group><article-title>Neurofibrillary tangles, amyotrophy and
progressive motor disturbance in mice expressing mutant (P301L) tau
protein</article-title><source>Nat Genet</source><year>2000</year><volume>25</volume><fpage>402</fpage><lpage>405</lpage><pub-id pub-id-type="doi">10.1038/78078</pub-id><pub-id pub-id-type="pmid">10932182</pub-id></element-citation></ref><ref id="CR81"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lue</surname><given-names>LF</given-names></name><name><surname>Walker</surname><given-names>DG</given-names></name><name><surname>Adler</surname><given-names>CH</given-names></name><name><surname>Shill</surname><given-names>H</given-names></name><name><surname>Tran</surname><given-names>H</given-names></name><name><surname>Akiyama</surname><given-names>H</given-names></name><name><surname>Sue</surname><given-names>LI</given-names></name><name><surname>Caviness</surname><given-names>J</given-names></name><name><surname>Sabbagh</surname><given-names>MN</given-names></name><name><surname>Beach</surname><given-names>TG</given-names></name></person-group><article-title>Biochemical increase in phosphorylated
&#x003b1;&#x02010;synuclein precedes histopathology of Lewy&#x02010;type
synucleinopathies</article-title><source>Brain Pathol</source><year>2012</year><volume>22</volume><fpage>745</fpage><lpage>756</lpage><pub-id pub-id-type="doi">10.1111/j.1750-3639.2012.00585.x</pub-id><pub-id pub-id-type="pmid">22369130</pub-id></element-citation></ref><ref id="CR82"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Auluck</surname><given-names>PK</given-names></name><name><surname>Caraveo</surname><given-names>G</given-names></name><name><surname>Lindquist</surname><given-names>S</given-names></name></person-group><article-title>&#x003b1;-Synuclein: membrane interactions and
toxicity in Parkinson&#x02019;s disease</article-title><source>Annu Rev Cell Dev Biol</source><year>2010</year><volume>26</volume><fpage>211</fpage><lpage>233</lpage><pub-id pub-id-type="doi">10.1146/annurev.cellbio.042308.113313</pub-id><pub-id pub-id-type="pmid">20500090</pub-id></element-citation></ref><ref id="CR83"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bartels</surname><given-names>T</given-names></name><name><surname>Ahlstrom</surname><given-names>LS</given-names></name><name><surname>Leftin</surname><given-names>A</given-names></name><name><surname>Kamp</surname><given-names>F</given-names></name><name><surname>Haass</surname><given-names>C</given-names></name><name><surname>Brown</surname><given-names>MF</given-names></name><name><surname>Beyer</surname><given-names>K</given-names></name></person-group><article-title>The N-terminus of the intrinsically
disordered protein &#x003b1;-synuclein triggers membrane binding and helix
folding</article-title><source>Biophys J</source><year>2010</year><volume>99</volume><fpage>2116</fpage><lpage>2124</lpage><pub-id pub-id-type="doi">10.1016/j.bpj.2010.06.035</pub-id><pub-id pub-id-type="pmid">20923645</pub-id></element-citation></ref><ref id="CR84"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uversky</surname><given-names>VN</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Fink</surname><given-names>AL</given-names></name></person-group><article-title>Metal-triggered structural transformations,
aggregation, and fibrillation of human &#x003b1;-synuclein - a possible
molecular link between Parkinson&#x02019;s disease and heavy metal
exposure</article-title><source>J Biol Chem</source><year>2001</year><volume>276</volume><fpage>44284</fpage><lpage>44296</lpage><pub-id pub-id-type="doi">10.1074/jbc.M105343200</pub-id><pub-id pub-id-type="pmid">11553618</pub-id></element-citation></ref><ref id="CR85"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sato</surname><given-names>H</given-names></name><name><surname>Arawaka</surname><given-names>S</given-names></name><name><surname>Hara</surname><given-names>S</given-names></name><name><surname>Fukushima</surname><given-names>S</given-names></name><name><surname>Koga</surname><given-names>K</given-names></name><name><surname>Koyama</surname><given-names>S</given-names></name><name><surname>Kato</surname><given-names>T</given-names></name></person-group><article-title>Authentically phosphorylated &#x003b1;-synuclein at
Ser129 accelerates neurodegeneration in a rat model of familial
Parkinson&#x02019;s disease</article-title><source>J Neurosci</source><year>2011</year><volume>31</volume><fpage>16884</fpage><lpage>16894</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.3967-11.2011</pub-id><pub-id pub-id-type="pmid">22090514</pub-id></element-citation></ref><ref id="CR86"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lou</surname><given-names>H</given-names></name><name><surname>Montoya</surname><given-names>SE</given-names></name><name><surname>Alerte</surname><given-names>TN</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Peng</surname><given-names>X</given-names></name><name><surname>Hong</surname><given-names>CS</given-names></name><name><surname>Friedrich</surname><given-names>EE</given-names></name><name><surname>Mader</surname><given-names>SA</given-names></name><name><surname>Pedersen</surname><given-names>CJ</given-names></name></person-group><article-title>Serine 129 phosphorylation reduces the
ability of &#x003b1;-synuclein to regulate tyrosine hydroxylase and protein
phosphatase 2A in vitro and in vivo</article-title><source>J Biol Chem</source><year>2010</year><volume>285</volume><fpage>17648</fpage><lpage>17661</lpage><pub-id pub-id-type="doi">10.1074/jbc.M110.100867</pub-id><pub-id pub-id-type="pmid">20356833</pub-id></element-citation></ref></ref-list></back></article>